{"recordsFiltered":49216,"recordsTotal":49216,"next":"http://staging-fdaaa.ebmdatalab.net/api/trials/?format=json&length=300&ordering=-title&start=45000","previous":"http://staging-fdaaa.ebmdatalab.net/api/trials/?format=json&length=300&ordering=-title&start=44400","results":[{"registry_id":"NCT06580054","publication_url":"https://clinicaltrials.gov/study/NCT06580054","title":"Pembrolizumab for Orbital and Periocular Cutaneous Squamous Cell Carcinoma (cSCC)","has_exemption":false,"start_date":"2025-03-05","completion_date":"2028-03-01","has_results":false,"results_due":false,"sponsor_name":"University of Michigan Rogel Cancer Center","sponsor_slug":"university-of-michigan-rogel-cancer-center","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06849713","publication_url":"https://clinicaltrials.gov/study/NCT06849713","title":"A Phase 2 Study of Zanubrutinib, Obinutuzumab, and Sonrotoclax in Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","has_exemption":false,"start_date":"2025-05-16","completion_date":"2028-03-01","has_results":false,"results_due":false,"sponsor_name":"Massachusetts General Hospital","sponsor_slug":"massachusetts-general-hospital","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06959511","publication_url":"https://clinicaltrials.gov/study/NCT06959511","title":"ZAnzalintinib Neoadjuvant EValuation in Thyroid Oncology (ZANEVO)","has_exemption":false,"start_date":"2025-07-22","completion_date":"2028-03-01","has_results":false,"results_due":false,"sponsor_name":"M.D. Anderson Cancer Center","sponsor_slug":"md-anderson-cancer-center","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05535361","publication_url":"https://clinicaltrials.gov/study/NCT05535361","title":"A Feasibility Study to Evaluate Safety and Probable Benefit of the Eclipse XL1 System for Distraction Enterogenesis in Adult and Pediatric Patients With Short Bowel Syndrome","has_exemption":false,"start_date":"2025-09-15","completion_date":"2028-03-01","has_results":false,"results_due":false,"sponsor_name":"Eclipse Regenesis, Inc.","sponsor_slug":"eclipse-regenesis-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07123454","publication_url":"https://clinicaltrials.gov/study/NCT07123454","title":"A Modular Phase I/II Open-label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Efficacy of AZD4512 Monotherapy or in Combination With Other Anticancer Agent(s), in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma (B-NHL) (Lumi-NHL)","has_exemption":false,"start_date":"2025-09-24","completion_date":"2028-03-01","has_results":false,"results_due":false,"sponsor_name":"AstraZeneca","sponsor_slug":"astrazeneca","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06934239","publication_url":"https://clinicaltrials.gov/study/NCT06934239","title":"A Randomized Controlled Trial Comparing Screening Mammography With and Without Assistance From Artificial Intelligence for Breast Cancer Detection and Recall Rates in Adult Patients","has_exemption":false,"start_date":"2025-10-15","completion_date":"2028-03-01","has_results":false,"results_due":false,"sponsor_name":"Jonsson Comprehensive Cancer Center","sponsor_slug":"jonsson-comprehensive-cancer-center","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06971731","publication_url":"https://clinicaltrials.gov/study/NCT06971731","title":"A Phase 3, Double-Blind, Randomized, Two-Period, Multicenter, Placebo-Controlled, Efficacy and Safety Study of JNT-517 for the Treatment of Participants With Phenylketonuria","has_exemption":false,"start_date":"2025-10-20","completion_date":"2028-03-01","has_results":false,"results_due":false,"sponsor_name":"Otsuka Pharmaceutical Development & Commercialization, Inc.","sponsor_slug":"otsuka-pharmaceutical-development-commercialization-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07025330","publication_url":"https://clinicaltrials.gov/study/NCT07025330","title":"A Phase IIa, Single-Site, Open-Label Study of Efgartigimod in Patients With IgG4-Related Disease","has_exemption":false,"start_date":"2025-11-12","completion_date":"2028-03-01","has_results":false,"results_due":false,"sponsor_name":"Stanford University","sponsor_slug":"stanford-university","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06377215","publication_url":"https://clinicaltrials.gov/study/NCT06377215","title":"Understanding Aided Speech Perception in Noise: Behavioral and Electrophysiological Measures","has_exemption":false,"start_date":"2025-11-16","completion_date":"2028-03-01","has_results":false,"results_due":false,"sponsor_name":"University of South Florida","sponsor_slug":"university-of-south-florida","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07265843","publication_url":"https://clinicaltrials.gov/study/NCT07265843","title":"Fibrinogen in Liver Transplant Subjects (FITS)","has_exemption":false,"start_date":"2026-01-01","completion_date":"2028-03-01","has_results":false,"results_due":false,"sponsor_name":"Trauma Hemostatis and Oxygenation Research (THOR) Network","sponsor_slug":"trauma-hemostatis-and-oxygenation-research-thor-network","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07270276","publication_url":"https://clinicaltrials.gov/study/NCT07270276","title":"The Impact of Dry Needling on Electrophysiological and Ultrasound-based Biomarkers for Myofascial Pain","has_exemption":false,"start_date":"2026-02-01","completion_date":"2028-03-01","has_results":false,"results_due":false,"sponsor_name":"Beth Israel Deaconess Medical Center","sponsor_slug":"beth-israel-deaconess-medical-center","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07101640","publication_url":"https://clinicaltrials.gov/study/NCT07101640","title":"Pharmacokinetics, Safety and Preliminary Efficacy Study of Montelukast in Critically Ill Infants With Developing Bronchopulmonary Dysplasia","has_exemption":false,"start_date":"2026-02-23","completion_date":"2028-03-01","has_results":false,"results_due":false,"sponsor_name":"Duke University","sponsor_slug":"duke-university","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07318688","publication_url":"https://clinicaltrials.gov/study/NCT07318688","title":"A Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of HMI-115 in Women With Moderate to Severe Endometriosis-Associated Pain Over a 24-Week Treatment Period and a 28-Week Extension","has_exemption":false,"start_date":"2026-03-01","completion_date":"2028-03-01","has_results":false,"results_due":false,"sponsor_name":"Hope Medicine (Nanjing) Co., Ltd","sponsor_slug":"hope-medicine-nanjing-co-ltd","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07369310","publication_url":"https://clinicaltrials.gov/study/NCT07369310","title":"Randomized Trial on DBS Programming Based on Biomarkers vs. Standard Monopolar Review","has_exemption":false,"start_date":"2026-03-01","completion_date":"2028-03-01","has_results":false,"results_due":false,"sponsor_name":"Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau","sponsor_slug":"fundacio-institut-de-recerca-de-lhospital-de-la-santa-creu-i-sant-pau","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07403058","publication_url":"https://clinicaltrials.gov/study/NCT07403058","title":"Endovascular Ablation Of The Right Greater Splanchnic Nerve In Subjects Having Heart Failure With Reduced Ejection Fraction: Randomized Controlled Feasibility Trial","has_exemption":false,"start_date":"2026-03-01","completion_date":"2028-03-01","has_results":false,"results_due":false,"sponsor_name":"Axon Therapies, Inc.","sponsor_slug":"axon-therapies-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07430917","publication_url":"https://clinicaltrials.gov/study/NCT07430917","title":"A Phase II, Randomized, Placebo-Controlled, Double-Blind, Adaptive Study to Assess the Safety and Efficacy of Intravenous J147 Combined With Endovascular Therapy in Patients With Acute Ischemic Stroke","has_exemption":false,"start_date":"2026-04-20","completion_date":"2028-03-01","has_results":false,"results_due":false,"sponsor_name":"Abrexa Pharmaceuticals, Inc.","sponsor_slug":"abrexa-pharmaceuticals-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07394608","publication_url":"https://clinicaltrials.gov/study/NCT07394608","title":"Use of Paired Non-Invasive Vagus Nerve Stimulation in Rehabilitation of Adolescents With Cerebral Palsy: An Open Label Safety Feasibility Trial","has_exemption":false,"start_date":"2026-04-30","completion_date":"2028-03-01","has_results":false,"results_due":false,"sponsor_name":"Icahn School of Medicine at Mount Sinai","sponsor_slug":"icahn-school-of-medicine-at-mount-sinai","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07251491","publication_url":"https://clinicaltrials.gov/study/NCT07251491","title":"Safety, Tolerability, Outcomes of Psilocybin for Depression (STOP Depression) in Veterans With Spinal Cord Injury","has_exemption":false,"start_date":"2026-05-01","completion_date":"2028-03-01","has_results":false,"results_due":false,"sponsor_name":"James J. Peters Veterans Affairs Medical Center","sponsor_slug":"james-j-peters-veterans-affairs-medical-center","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07410598","publication_url":"https://clinicaltrials.gov/study/NCT07410598","title":"Safety and Tolerability of Patterned Stimulation for DBS in the Home Setting","has_exemption":false,"start_date":"2026-05-06","completion_date":"2028-03-01","has_results":false,"results_due":false,"sponsor_name":"University of Florida","sponsor_slug":"university-of-florida","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07377526","publication_url":"https://clinicaltrials.gov/study/NCT07377526","title":"Phase 1/2 Study Of IL15-Transduced, TGFBR2 KO, TROP2 CAR- Engineered Cord Blood-Derived NK Cells Administered Intraperitoneally And Intravenously In Combination With Oral Belzutifan For The Management Of Pancreatic Cancer","has_exemption":false,"start_date":"2026-05-26","completion_date":"2028-03-01","has_results":false,"results_due":false,"sponsor_name":"M.D. Anderson Cancer Center","sponsor_slug":"md-anderson-cancer-center","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07215858","publication_url":"https://clinicaltrials.gov/study/NCT07215858","title":"Randomized, Double-Blinded, Placebo-Controlled, Phase 2 Study of the Safety and Efficacy of BPL-1357 Against H1N1 Influenza Virus Challenge","has_exemption":false,"start_date":"2026-06-23","completion_date":"2028-03-01","has_results":false,"results_due":false,"sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","sponsor_slug":"national-institute-of-allergy-and-infectious-diseases-niaid","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07405190","publication_url":"https://clinicaltrials.gov/study/NCT07405190","title":"A Phase II Study of Ivonescimab as Monotherapy or in Combination With Platinum/Pemetrexed Chemotherapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Harboring Actionable Genomic Alterations (AGAs)","has_exemption":false,"start_date":"2026-08-04","completion_date":"2028-03-01","has_results":false,"results_due":false,"sponsor_name":"Massachusetts General Hospital","sponsor_slug":"massachusetts-general-hospital","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT03571945","publication_url":"https://clinicaltrials.gov/study/NCT03571945","title":"Impact of Bi-spectral Index Guided Inhalation Anaesthesia on the Incidence of Intraoperative Awareness in Indian Patient Population: A Prospective, Randomised, Multi-Centric Study","has_exemption":false,"start_date":"2018-10-10","completion_date":"2028-03-02","has_results":false,"results_due":false,"sponsor_name":"Sir Ganga Ram Hospital","sponsor_slug":"sir-ganga-ram-hospital","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05732402","publication_url":"https://clinicaltrials.gov/study/NCT05732402","title":"An Open-Label, Multiple-Ascending Dose Study to Assess the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Different Dose Levels of Povetacicept in Subjects With Autoantibody-Associated Glomerular Diseases (RUBY-3)","has_exemption":false,"start_date":"2023-03-15","completion_date":"2028-03-02","has_results":false,"results_due":false,"sponsor_name":"Alpine Immune Sciences, Inc.","sponsor_slug":"alpine-immune-sciences-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06676579","publication_url":"https://clinicaltrials.gov/study/NCT06676579","title":"A Multi-Center, Phase II, Open Label, Randomized Trial Evaluating the Efficacy and Safety of Complement 5a Receptor Antagonist Avacopan in Crescentic IgA Nephropathy","has_exemption":false,"start_date":"2025-06-09","completion_date":"2028-03-02","has_results":false,"results_due":false,"sponsor_name":"Mayo Clinic","sponsor_slug":"mayo-clinic","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07586202","publication_url":"https://clinicaltrials.gov/study/NCT07586202","title":"A Phase 2 Study Evaluating the Safety and Efficacy of Neoadjuvant Amivantamab in Combination With Lazertinib or Chemotherapy in Resectable EGFR-Mutated Non-Small Cell Lung Cancer","has_exemption":false,"start_date":"2026-07-17","completion_date":"2028-03-02","has_results":false,"results_due":false,"sponsor_name":"Janssen Research & Development, LLC","sponsor_slug":"janssen-research-development-llc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05402332","publication_url":"https://clinicaltrials.gov/study/NCT05402332","title":"A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-Controlled, Crossover, Trial Assessing the Efficacy, Safety, and Tolerability of AVTX-801 in Subjects With Phosphoglucomutase 1 Deficiency Related Congenital Disorders of Glycosylation (PGM1-CDG)","has_exemption":false,"start_date":"2026-10-01","completion_date":"2028-03-02","has_results":false,"results_due":false,"sponsor_name":"Eva Morava-Kozicz","sponsor_slug":"eva-morava-kozicz","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05834296","publication_url":"https://clinicaltrials.gov/study/NCT05834296","title":"Randomized, Double-blind, Placebo-controlled, Parallel-group, Phase 1/2a Study to Assess Safety, Tolerability & Efficacy of Autologous Beta-Amyloid Mutant Peptide-pulsed Dendritic Cells in Subjects With Mild-to-Moderate Alzheimer's Dementia","has_exemption":false,"start_date":"2023-07-05","completion_date":"2028-03-03","has_results":false,"results_due":false,"sponsor_name":"Alzamend Neuro, Inc.","sponsor_slug":"alzamend-neuro-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07447063","publication_url":"https://clinicaltrials.gov/study/NCT07447063","title":"The Impact of Dietary Salt on the Severity of Eczema","has_exemption":false,"start_date":"2026-06-22","completion_date":"2028-03-05","has_results":false,"results_due":false,"sponsor_name":"University of California, San Francisco","sponsor_slug":"university-of-california-san-francisco","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07332091","publication_url":"https://clinicaltrials.gov/study/NCT07332091","title":"A Phase 2, Multicenter, Randomized, Placebo-controlled, Double-blind Study of the Efficacy and Safety of Vamifeport in Adult Subjects With HFE-related Hereditary Hemochromatosis (FERROCLEAR Study)","has_exemption":false,"start_date":"2026-01-22","completion_date":"2028-03-06","has_results":false,"results_due":false,"sponsor_name":"CSL Behring","sponsor_slug":"csl-behring","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT03471650","publication_url":"https://clinicaltrials.gov/study/NCT03471650","title":"A Phase II Study to Evaluate the Performance of PSMA-targeted 18F-DCFPyL PET/CT for the Detection of Clinically Significant Prostate Cancer in Men With an Elevated PSA","has_exemption":false,"start_date":"2018-03-29","completion_date":"2028-03-07","has_results":false,"results_due":false,"sponsor_name":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","sponsor_slug":"sidney-kimmel-comprehensive-cancer-center-at-johns-hopkins","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07284420","publication_url":"https://clinicaltrials.gov/study/NCT07284420","title":"An ISA to Master Protocol ARGX-999-2-MG-2000 for an Exploratory, Phase 2a, Proof-of-Concept Study to Evaluate the Safety, Tolerability, and Efficacy of Empasiprubart IV as Add-On Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod","has_exemption":false,"start_date":"2025-12-19","completion_date":"2028-03-07","has_results":false,"results_due":false,"sponsor_name":"argenx","sponsor_slug":"argenx","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06852963","publication_url":"https://clinicaltrials.gov/study/NCT06852963","title":"A Repeat-Dose, Open-Label, Two Arm Safety and Efficacy Study of Two Doses of VP-001 (30 μg and 75 μg) Administered Intravitreally in Participants With Confirmed PRPF31 Mutation-Associated Retinal Dystrophy, Including Participants Previously Treated With VP001 in the PLATYPUS Study (Protocol # VP001-101) or WALLABY Study (Protocol # VP001-102) for a Minimum of 8 Weeks","has_exemption":false,"start_date":"2025-06-01","completion_date":"2028-03-08","has_results":false,"results_due":false,"sponsor_name":"PYC Therapeutics","sponsor_slug":"pyc-therapeutics","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06928662","publication_url":"https://clinicaltrials.gov/study/NCT06928662","title":"Sequential Decitabine in Combination With FLAG-Ida Followed Immediately by Reduced-Intensity Conditioning (RIC) Allogeneic Hematopoietic Cell Transplantation (DEC-FLAG-Ida/RIC) for Adults With Myeloid Malignancies at High Risk of Relapse: A Phase 1/2 Study","has_exemption":false,"start_date":"2025-09-23","completion_date":"2028-03-09","has_results":false,"results_due":false,"sponsor_name":"Fred Hutchinson Cancer Center","sponsor_slug":"fred-hutchinson-cancer-center","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT04276870","publication_url":"https://clinicaltrials.gov/study/NCT04276870","title":"CD19-Directed Chimeric Antigen Receptor CD19 Redirected Autologous T Cells (CART19) for Orphan Indications of Pediatric B Cell Acute Lymphoblastic Leukemia (B ALL)","has_exemption":false,"start_date":"2020-03-12","completion_date":"2028-03-10","has_results":false,"results_due":false,"sponsor_name":"Stephan Grupp MD PhD","sponsor_slug":"stephan-grupp-md-phd","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07144280","publication_url":"https://clinicaltrials.gov/study/NCT07144280","title":"PADL1NK-005: A Randomized, Phase 3, Open-Label Study to Evaluate PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)","has_exemption":false,"start_date":"2025-09-29","completion_date":"2028-03-10","has_results":false,"results_due":false,"sponsor_name":"Pfizer","sponsor_slug":"pfizer","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07335588","publication_url":"https://clinicaltrials.gov/study/NCT07335588","title":"A Phase 3, Double-blinded, Vehicle-controlled Trial to Investigate the Efficacy and Safety of Twice Daily Delgocitinib Cream in Adult Participants With Lichen Sclerosus During a 12-Week Initial Treatment Period Followed by a 40-Week Continuation Treatment Period","has_exemption":false,"start_date":"2026-05-01","completion_date":"2028-03-10","has_results":false,"results_due":false,"sponsor_name":"LEO Pharma","sponsor_slug":"leo-pharma","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07615686","publication_url":"https://clinicaltrials.gov/study/NCT07615686","title":"Transcutaneous Spinal Cord Stimulation to Improve Strength and Gait in Children With Spina Bifida","has_exemption":false,"start_date":"2026-06-10","completion_date":"2028-03-10","has_results":false,"results_due":false,"sponsor_name":"Bailey Petersen","sponsor_slug":"bailey-petersen","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06926868","publication_url":"https://clinicaltrials.gov/study/NCT06926868","title":"IZABRIGHT-Breast01: A Randomized, Open-label, Inferentially Seamless Phase 2/3 Study of Izalontamab Brengitecan (BMS-986507) Versus Treatment of Physician's Choice in Patients With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer (TNBC) or ER-low, HER2-negative BC Who Are Ineligible for Anti-PD1/PD-L1 Treatment","has_exemption":false,"start_date":"2025-09-11","completion_date":"2028-03-13","has_results":false,"results_due":false,"sponsor_name":"Bristol-Myers Squibb","sponsor_slug":"bristol-myers-squibb","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06453044","publication_url":"https://clinicaltrials.gov/study/NCT06453044","title":"A Phase 2 Study of Mosunetuzumab With Polatuzumab Vedotin in Patients With Relapsed/Refractory Follicular Lymphoma","has_exemption":false,"start_date":"2024-09-09","completion_date":"2028-03-14","has_results":false,"results_due":false,"sponsor_name":"City of Hope Medical Center","sponsor_slug":"city-of-hope-medical-center","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT01295645","publication_url":"https://clinicaltrials.gov/study/NCT01295645","title":"A Phase II Randomized Study of Cidofovir Versus Best Supportive Care for Polyomavirus Hominis Type I (BK) Virus Related Hemorrhagic Cystitis After Stem Cell Transplant","has_exemption":false,"start_date":"2011-03-17","completion_date":"2028-03-15","has_results":false,"results_due":false,"sponsor_name":"M.D. Anderson Cancer Center","sponsor_slug":"md-anderson-cancer-center","status":"ongoing","is_pact":true,"days_late":null},{"registry_id":"NCT06245109","publication_url":"https://clinicaltrials.gov/study/NCT06245109","title":"Brain-Based and Clinical Phenotyping of Pain Pharmacotherapy in Knee Osteoarthritis","has_exemption":false,"start_date":"2024-02-26","completion_date":"2028-03-15","has_results":false,"results_due":false,"sponsor_name":"Northwestern University","sponsor_slug":"northwestern-university","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06616766","publication_url":"https://clinicaltrials.gov/study/NCT06616766","title":"A Phase 1/2, Open-label, Multicenter, FIH Study to Evaluate the Safety, Tolerability, PK and Anti-tumor Activity of YH42946 in Patients With Locally Advanced or Metastatic Solid Tumors With HER2 Aberration and EGFR Exon 20 Insertion","has_exemption":false,"start_date":"2024-10-02","completion_date":"2028-03-15","has_results":false,"results_due":false,"sponsor_name":"Yuhan Corporation","sponsor_slug":"yuhan-corporation","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06605105","publication_url":"https://clinicaltrials.gov/study/NCT06605105","title":"A Phase III Long-Term Extension Trial With Optional Additional Doses of CYB003 to Assess the Safety and Long-term Efficacy in Participants With Major Depressive Disorder (EXTEND)","has_exemption":false,"start_date":"2025-07-18","completion_date":"2028-03-15","has_results":false,"results_due":false,"sponsor_name":"Cybin IRL Limited","sponsor_slug":"cybin-irl-limited","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06747611","publication_url":"https://clinicaltrials.gov/study/NCT06747611","title":"Evaluation of Microbiota Transplant Therapy in Patients With Alopecia Areata","has_exemption":false,"start_date":"2025-08-21","completion_date":"2028-03-15","has_results":false,"results_due":false,"sponsor_name":"University of Minnesota","sponsor_slug":"university-of-minnesota","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06722235","publication_url":"https://clinicaltrials.gov/study/NCT06722235","title":"A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy and Safety of Mezagitamab Subcutaneous Injection in Participants With Chronic Primary Immune Thrombocytopenia","has_exemption":false,"start_date":"2025-02-27","completion_date":"2028-03-16","has_results":false,"results_due":false,"sponsor_name":"Takeda","sponsor_slug":"takeda","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07487831","publication_url":"https://clinicaltrials.gov/study/NCT07487831","title":"The Impact of Salt Intake on Sodium in the Skin and Inflammatory Skin Disease","has_exemption":false,"start_date":"2026-06-22","completion_date":"2028-03-17","has_results":false,"results_due":false,"sponsor_name":"University of California, San Francisco","sponsor_slug":"university-of-california-san-francisco","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07476287","publication_url":"https://clinicaltrials.gov/study/NCT07476287","title":"A PHASE 2 INTERVENTIONAL STUDY OF PF-08634404 IN COMBINATION WITH CHEMOTHERAPY IN PARTICIPANTS WITH PREVIOUSLY UNTREATED TRANSFORMED SMALL CELL LUNG CANCER","has_exemption":false,"start_date":"2026-05-15","completion_date":"2028-03-19","has_results":false,"results_due":false,"sponsor_name":"Pfizer","sponsor_slug":"pfizer","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06305247","publication_url":"https://clinicaltrials.gov/study/NCT06305247","title":"An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours","has_exemption":false,"start_date":"2024-04-03","completion_date":"2028-03-20","has_results":false,"results_due":false,"sponsor_name":"Ipsen","sponsor_slug":"ipsen","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07284979","publication_url":"https://clinicaltrials.gov/study/NCT07284979","title":"A Phase 3, Randomized, Active- and Placebo-Controlled, Partially-Blinded Study to Compare the Efficacy and Safety of KAI-9531 Administered Once Weekly Versus Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes","has_exemption":false,"start_date":"2025-12-30","completion_date":"2028-03-20","has_results":false,"results_due":false,"sponsor_name":"Kailera","sponsor_slug":"kailera","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05025800","publication_url":"https://clinicaltrials.gov/study/NCT05025800","title":"A Phase I/II Open Label, Single Center, Study of the Combination of ALX148, Rituximab and Lenalidomide in Patients With Indolent and Aggressive B-Cell Non-Hodgkin Lymphoma","has_exemption":false,"start_date":"2021-10-13","completion_date":"2028-03-21","has_results":false,"results_due":false,"sponsor_name":"M.D. Anderson Cancer Center","sponsor_slug":"md-anderson-cancer-center","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05160922","publication_url":"https://clinicaltrials.gov/study/NCT05160922","title":"CRIZOTINIB MASTER PROTOCOL: AN OPEN-LABEL CONTINUATION STUDY FOR PARTICIPANTS CONTINUING FROM PFIZER-SPONSORED CRIZOTINIB CLINICAL STUDIES","has_exemption":false,"start_date":"2021-12-27","completion_date":"2028-03-21","has_results":false,"results_due":false,"sponsor_name":"Pfizer","sponsor_slug":"pfizer","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT04804553","publication_url":"https://clinicaltrials.gov/study/NCT04804553","title":"A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Apremilast in Children From 5 to Less Than 18 Years of Age With Active Juvenile Psoriatic Arthritis (PEAPOD)","has_exemption":false,"start_date":"2022-03-17","completion_date":"2028-03-21","has_results":false,"results_due":false,"sponsor_name":"Amgen","sponsor_slug":"amgen","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06350097","publication_url":"https://clinicaltrials.gov/study/NCT06350097","title":"A Phase III, Open-label, Randomised Study of Osimertinib With or Without Datopotamab Deruxtecan (Dato-DXd), as First-line Treatment in Participants With Epidermal Growth Factor Receptor (EGFR) Mutation-positive, Locally Advanced or Metastatic Non-small Cell Lung Cancer","has_exemption":false,"start_date":"2024-04-29","completion_date":"2028-03-21","has_results":false,"results_due":false,"sponsor_name":"AstraZeneca","sponsor_slug":"astrazeneca","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06597019","publication_url":"https://clinicaltrials.gov/study/NCT06597019","title":"Two Part (Double-blind Inclisiran Versus Placebo [Year 1] Followed by Open-label Inclisiran [Year 2]) Randomized Multicenter Study to Evaluate Safety, Tolerability and Efficacy of Inclisiran in Children (6 to Less Than 12 Years) With Heterozygous Familial Hypercholesterolemia and Elevated LDL- Cholesterol","has_exemption":false,"start_date":"2024-12-09","completion_date":"2028-03-21","has_results":false,"results_due":false,"sponsor_name":"Novartis Pharmaceuticals","sponsor_slug":"novartis-pharmaceuticals","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06597006","publication_url":"https://clinicaltrials.gov/study/NCT06597006","title":"Two Part (Double-blind Inclisiran Versus Placebo [Year 1] Followed by Open-label Inclisiran [Year 2]) Randomized Multicenter Study to Evaluate Safety, Tolerability, and Efficacy of Inclisiran in Children (2 to Less Than 12 Years) With Homozygous Familial Hypercholesterolemia and Elevated LDL-cholesterol","has_exemption":false,"start_date":"2025-02-28","completion_date":"2028-03-23","has_results":false,"results_due":false,"sponsor_name":"Novartis Pharmaceuticals","sponsor_slug":"novartis-pharmaceuticals","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06141486","publication_url":"https://clinicaltrials.gov/study/NCT06141486","title":"A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis","has_exemption":false,"start_date":"2023-12-27","completion_date":"2028-03-24","has_results":false,"results_due":false,"sponsor_name":"Sanofi","sponsor_slug":"sanofi","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07221188","publication_url":"https://clinicaltrials.gov/study/NCT07221188","title":"A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Study to Investigate the Safety and Tolerability of Efimosfermin Alfa in Participants With Known or Suspected F2- or F3-Stage Metabolic Dysfunction-Associated Steatohepatitis (MASH) (ZENITH-2)","has_exemption":false,"start_date":"2025-12-12","completion_date":"2028-03-24","has_results":false,"results_due":false,"sponsor_name":"GlaxoSmithKline","sponsor_slug":"glaxosmithkline","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07332455","publication_url":"https://clinicaltrials.gov/study/NCT07332455","title":"A Phase 1/2 First-Time-in-Human, Open-label, Multicenter, Dose Escalation and Dose Optimization Study of GSK5471713 in Adult Participants With Metastatic Castration Resistant Prostate Cancer (mCRPC)","has_exemption":false,"start_date":"2026-02-10","completion_date":"2028-03-24","has_results":false,"results_due":false,"sponsor_name":"GlaxoSmithKline","sponsor_slug":"glaxosmithkline","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07213973","publication_url":"https://clinicaltrials.gov/study/NCT07213973","title":"A Phase 2, Open-Label Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Povorcitinib in Adolescents With Moderate to Severe Hidradenitis Suppurativa","has_exemption":false,"start_date":"2026-02-02","completion_date":"2028-03-25","has_results":false,"results_due":false,"sponsor_name":"Incyte Corporation","sponsor_slug":"incyte-corporation","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05530421","publication_url":"https://clinicaltrials.gov/study/NCT05530421","title":"Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma (SELVEDge Study)","has_exemption":false,"start_date":"2023-03-26","completion_date":"2028-03-26","has_results":false,"results_due":false,"sponsor_name":"University of Miami","sponsor_slug":"university-of-miami","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07284901","publication_url":"https://clinicaltrials.gov/study/NCT07284901","title":"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of KAI-9531 Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes","has_exemption":false,"start_date":"2026-01-12","completion_date":"2028-03-27","has_results":false,"results_due":false,"sponsor_name":"Kailera","sponsor_slug":"kailera","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05616910","publication_url":"https://clinicaltrials.gov/study/NCT05616910","title":"Inhaled Nitric Oxide for Microvascular Dysfunction in Traumatic Brain Injury","has_exemption":false,"start_date":"2025-04-06","completion_date":"2028-03-28","has_results":false,"results_due":false,"sponsor_name":"University of Pennsylvania","sponsor_slug":"university-of-pennsylvania","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06939348","publication_url":"https://clinicaltrials.gov/study/NCT06939348","title":"Safety and Efficacy of Thalamic Focused Ultrasound Stimulation (tFUS) for Promoting Recovery After Severe Traumatic Brain Injury","has_exemption":false,"start_date":"2025-04-26","completion_date":"2028-03-28","has_results":false,"results_due":false,"sponsor_name":"University of California, Los Angeles","sponsor_slug":"university-of-california-los-angeles","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07136181","publication_url":"https://clinicaltrials.gov/study/NCT07136181","title":"A Multicenter Phase Ib/II Study to Evaluate the Safety, Efficacy and Pharmacokinetics of NBM-BMX in Patients With Metastatic Uveal Melanoma","has_exemption":false,"start_date":"2025-11-20","completion_date":"2028-03-28","has_results":false,"results_due":false,"sponsor_name":"Novelwise Pharmaceutical Corporation","sponsor_slug":"novelwise-pharmaceutical-corporation","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07508787","publication_url":"https://clinicaltrials.gov/study/NCT07508787","title":"Phase 2b, Randomized, Multicenter, Double-Blind, Dose-Finding, Active-Controlled Study of Siplizumab (TCD601) Compared to Rabbit Anti-Thymocyte Globulin in Renal Transplant Recipients Requiring Induction Therapy and Receiving Standard of Care Immunosuppression With Tacrolimus, Mycophenolic Acid and Corticosteroids","has_exemption":false,"start_date":"2026-04-29","completion_date":"2028-03-28","has_results":false,"results_due":false,"sponsor_name":"Nefro Avillion Clinical Development, LLC","sponsor_slug":"nefro-avillion-clinical-development-llc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07290140","publication_url":"https://clinicaltrials.gov/study/NCT07290140","title":"A Randomized, Controlled, Blinded, Multi-Center Trial to Assess the Safety and Efficacy of Paclitaxel-Coated Sinus Balloon as an Adjunct to Endoscopic Sinus Surgery in Adult Chronic Rhinosinusitis Subjects","has_exemption":false,"start_date":"2026-06-01","completion_date":"2028-03-28","has_results":false,"results_due":false,"sponsor_name":"Airiver Medical, Inc.","sponsor_slug":"airiver-medical-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07221227","publication_url":"https://clinicaltrials.gov/study/NCT07221227","title":"A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Study to Investigate the Safety and Efficacy of Efimosfermin Alfa in Participants With Biopsy-Confirmed F2- or F3-Stage Metabolic Dysfunction-Associated Steatohepatitis (MASH) (ZENITH-1)","has_exemption":false,"start_date":"2025-10-24","completion_date":"2028-03-29","has_results":false,"results_due":false,"sponsor_name":"GlaxoSmithKline","sponsor_slug":"glaxosmithkline","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07298473","publication_url":"https://clinicaltrials.gov/study/NCT07298473","title":"Conquer-AF Protocol for Redo Ablation Procedures in Recurrent Paroxysmal and Persistent Atrial Fibrillation Using the Sphere-9 Catheter and Affera Ablation System (Conquer-AF)","has_exemption":false,"start_date":"2026-04-08","completion_date":"2028-03-29","has_results":false,"results_due":false,"sponsor_name":"Medtronic Cardiac Ablation Solutions","sponsor_slug":"medtronic-cardiac-ablation-solutions","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT03950609","publication_url":"https://clinicaltrials.gov/study/NCT03950609","title":"A Phase II Study of Lenvatinib in Combination With Everolimus in Patients With Advanced Carcinoid Tumors","has_exemption":false,"start_date":"2019-07-30","completion_date":"2028-03-30","has_results":false,"results_due":false,"sponsor_name":"M.D. Anderson Cancer Center","sponsor_slug":"md-anderson-cancer-center","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05027633","publication_url":"https://clinicaltrials.gov/study/NCT05027633","title":"Immunotherapy With Chemotherapy and Chemoradiation for Advanced Squamous Cancer of Nasal Cavity / Paranasal Sinuses (I-NAPA)","has_exemption":false,"start_date":"2021-11-02","completion_date":"2028-03-30","has_results":false,"results_due":false,"sponsor_name":"M.D. Anderson Cancer Center","sponsor_slug":"md-anderson-cancer-center","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05316155","publication_url":"https://clinicaltrials.gov/study/NCT05316155","title":"Phase 1/2 Study of Erdafitinib Intravesical Delivery System (TAR-210) in Participants With Non-Muscle-Invasive or Muscle-Invasive Bladder Cancer","has_exemption":false,"start_date":"2022-04-11","completion_date":"2028-03-30","has_results":false,"results_due":false,"sponsor_name":"Janssen Research & Development, LLC","sponsor_slug":"janssen-research-development-llc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05811364","publication_url":"https://clinicaltrials.gov/study/NCT05811364","title":"The GORE VBX FORWARD Clinical Study: A Comparison of the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis to Bare Metal Stenting for Patients With Complex Iliac Occlusive Disease","has_exemption":false,"start_date":"2023-10-17","completion_date":"2028-03-30","has_results":false,"results_due":false,"sponsor_name":"W.L.Gore & Associates","sponsor_slug":"wlgore-associates","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06091865","publication_url":"https://clinicaltrials.gov/study/NCT06091865","title":"A Phase 3, Open Label, Randomized Study Comparing the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20 × Anti-CD3 Bispecific Antibody, in Combination With CHOP (ODRO-CHOP) Versus Rituximab in Combination With CHOP (R-CHOP) in Previously Untreated Participants With Diffuse Large B-cell Lymphoma (DLBCL) (OLYMPIA-3)","has_exemption":false,"start_date":"2023-12-13","completion_date":"2028-03-30","has_results":false,"results_due":false,"sponsor_name":"Regeneron Pharmaceuticals","sponsor_slug":"regeneron-pharmaceuticals","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06213324","publication_url":"https://clinicaltrials.gov/study/NCT06213324","title":"Neural Circuit-Specific Mechanisms of Ketamine's Effect on Anhedonia and Anxiety in Depression Using Ultra-High Field 7-Tesla MRI","has_exemption":false,"start_date":"2024-01-31","completion_date":"2028-03-30","has_results":false,"results_due":false,"sponsor_name":"Icahn School of Medicine at Mount Sinai","sponsor_slug":"icahn-school-of-medicine-at-mount-sinai","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06644768","publication_url":"https://clinicaltrials.gov/study/NCT06644768","title":"A Multicenter, Randomized, Open-Label, Phase 1b/2 Trial Of Valemetostat Tosylate Plus Pembrolizumab Vs Pembrolizumab Alone in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Whose Tumors Express PD-L1 With Tumor Proportion Score ≥50% Without Actionable Genomic Alterations","has_exemption":false,"start_date":"2024-10-30","completion_date":"2028-03-30","has_results":false,"results_due":false,"sponsor_name":"Daiichi Sankyo","sponsor_slug":"daiichi-sankyo","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06877650","publication_url":"https://clinicaltrials.gov/study/NCT06877650","title":"A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of JMT108 Injection in Participants With Advanced Malignant Tumors.","has_exemption":false,"start_date":"2025-04-11","completion_date":"2028-03-30","has_results":false,"results_due":false,"sponsor_name":"Shanghai JMT-Bio Inc.","sponsor_slug":"shanghai-jmt-bio-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06905054","publication_url":"https://clinicaltrials.gov/study/NCT06905054","title":"Peroxisome Proliferator-Activated Receptor Agonists to Prevent Primary Sclerosing Cholangitis Recurrence After Liver Transplantation","has_exemption":false,"start_date":"2025-04-15","completion_date":"2028-03-30","has_results":false,"results_due":false,"sponsor_name":"Mayo Clinic","sponsor_slug":"mayo-clinic","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07166757","publication_url":"https://clinicaltrials.gov/study/NCT07166757","title":"A Phase I/II Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of Human Allogeneic Induced Pluripotent Stem Cell-derived Dopaminergic Neural Progenitor Cell Injection in the Treatment of Early-onset Parkinson's Disease","has_exemption":false,"start_date":"2025-09-22","completion_date":"2028-03-30","has_results":false,"results_due":false,"sponsor_name":"XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd.","sponsor_slug":"xellsmart-bio-pharmaceutical-suzhou-co-ltd","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07169175","publication_url":"https://clinicaltrials.gov/study/NCT07169175","title":"A Multicenter, Open-label, Single-arm, Dose Escalation and Expansion, Phase I/IIa Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of SNUG01 in Adult Subjects With Amyotrophic Lateral Sclerosis (ALS)","has_exemption":false,"start_date":"2025-12-01","completion_date":"2028-03-30","has_results":false,"results_due":false,"sponsor_name":"SineuGene Therapeutics Co., Ltd.","sponsor_slug":"sineugene-therapeutics-co-ltd","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07115329","publication_url":"https://clinicaltrials.gov/study/NCT07115329","title":"Phase 2, Multicenter, Randomized, Double-Blind Evaluation of the Efficacy and Safety of Oral GATE-251 or Placebo for the Reduction of Symptoms of Major Depressive Disorder","has_exemption":false,"start_date":"2026-01-05","completion_date":"2028-03-30","has_results":false,"results_due":false,"sponsor_name":"Syndeio Biosciences, Inc","sponsor_slug":"syndeio-biosciences-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07350174","publication_url":"https://clinicaltrials.gov/study/NCT07350174","title":"A Multicenter, Open-label, Randomized, Active-controlled, Phase 2a Study to Evaluate the Pharmacokinetics and Safety of Alpibectir/Ethionamide in Combination With the Standard Regimen in Patients With Tuberculosis Meningitis.","has_exemption":false,"start_date":"2026-03-30","completion_date":"2028-03-30","has_results":false,"results_due":false,"sponsor_name":"BioVersys AG","sponsor_slug":"bioversys-ag","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07594158","publication_url":"https://clinicaltrials.gov/study/NCT07594158","title":"A Multicenter, Open-label Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ONO-2017 in Japanese Patients With Partial Onset Seizures Aged 2 to Under 18 Years.","has_exemption":false,"start_date":"2026-05-30","completion_date":"2028-03-30","has_results":false,"results_due":false,"sponsor_name":"Ono Pharmaceutical Co. Ltd","sponsor_slug":"ono-pharmaceutical-co-ltd","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07642284","publication_url":"https://clinicaltrials.gov/study/NCT07642284","title":"A Prospective, Parallel-group, Randomized Clinical Investigation Evaluating Performance and Safety of the AH Plus Jet® Sealing Materials Used in Single-cone Technique for Single Visit Endodontic Treatment. A 2-year Follow-up Study","has_exemption":false,"start_date":"2026-05-30","completion_date":"2028-03-30","has_results":false,"results_due":false,"sponsor_name":"Dentsply Sirona Implants and Consumables","sponsor_slug":"dentsply-sirona-implants-and-consumables","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07403968","publication_url":"https://clinicaltrials.gov/study/NCT07403968","title":"An Open-Label, Single-Arm, Phase 2a Trial to Evaluate the Safety, Tolerability, PK, and Mechanism of Action of Zasocitinib (TAK-279) in Participants With Active Crohn's Disease","has_exemption":false,"start_date":"2026-06-15","completion_date":"2028-03-30","has_results":false,"results_due":false,"sponsor_name":"Takeda","sponsor_slug":"takeda","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT03514329","publication_url":"https://clinicaltrials.gov/study/NCT03514329","title":"Vapor Ablation for Localized Cancer Lesions of the Lung - A Clinical Feasibility Definitive Treatment Study","has_exemption":false,"start_date":"2026-09-01","completion_date":"2028-03-30","has_results":false,"results_due":false,"sponsor_name":"Uptake Medical Technology, Inc.","sponsor_slug":"uptake-medical-technology-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT03414502","publication_url":"https://clinicaltrials.gov/study/NCT03414502","title":"Treatment of Rheumatoid Arthritis With Disease-modifying Antirheumatic Drugs (DMARDs): Predictors of Response","has_exemption":false,"start_date":"2007-12-10","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"University of Nebraska","sponsor_slug":"university-of-nebraska","status":"ongoing","is_pact":true,"days_late":null},{"registry_id":"NCT02174549","publication_url":"https://clinicaltrials.gov/study/NCT02174549","title":"Phase I Dose-Escalating Study of Combining Intravenous Tirapazamine and Transarterial Embolization (TAE) in Liver Cancer","has_exemption":false,"start_date":"2014-09-30","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"Teclison Ltd.","sponsor_slug":"teclison-ltd","status":"ongoing","is_pact":true,"days_late":null},{"registry_id":"NCT02324387","publication_url":"https://clinicaltrials.gov/study/NCT02324387","title":"Assessment of the Tumor Response to Neoadjuvant Chemotherapy in Women With Locoregional Invasive Breast Cancer Using Tc99m Sestamibi Molecular Breast Imaging: A Prospective Study","has_exemption":false,"start_date":"2015-06-15","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"M.D. Anderson Cancer Center","sponsor_slug":"md-anderson-cancer-center","status":"ongoing","is_pact":true,"days_late":null},{"registry_id":"NCT02710968","publication_url":"https://clinicaltrials.gov/study/NCT02710968","title":"Study of Fetoscopic Endoluminal Tracheal Occlusion (FETO) in Fetuses With Severe Left Congenital Diaphragmatic Hernia (CDH)","has_exemption":false,"start_date":"2015-08-31","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"Johns Hopkins University","sponsor_slug":"johns-hopkins-university","status":"ongoing","is_pact":true,"days_late":null},{"registry_id":"NCT02629809","publication_url":"https://clinicaltrials.gov/study/NCT02629809","title":"First-Line Therapy With Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (GA-101) (iFCG) for Patients With Chronic Lymphocytic Leukemia (CLL) With Mutated IGHV Gene and Non-Del(17p)","has_exemption":false,"start_date":"2016-03-18","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"M.D. Anderson Cancer Center","sponsor_slug":"md-anderson-cancer-center","status":"ongoing","is_pact":true,"days_late":null},{"registry_id":"NCT02742883","publication_url":"https://clinicaltrials.gov/study/NCT02742883","title":"A Phase 2 Study of Atengenal (A-10) and Astugenal (AS2-1) in Diffuse, Intrinsic Pontine Glioma (DIPG)","has_exemption":false,"start_date":"2016-04-13","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"Burzynski Research Institute","sponsor_slug":"burzynski-research-institute","status":"ongoing","is_pact":true,"days_late":null},{"registry_id":"NCT02703623","publication_url":"https://clinicaltrials.gov/study/NCT02703623","title":"A Dynamic Allocation Modular Sequential Trial of Approved and Promising Therapies in Men With Metastatic Castrate Resistant Prostate Cancer","has_exemption":false,"start_date":"2016-05-18","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"M.D. Anderson Cancer Center","sponsor_slug":"md-anderson-cancer-center","status":"ongoing","is_pact":true,"days_late":null},{"registry_id":"NCT03011684","publication_url":"https://clinicaltrials.gov/study/NCT03011684","title":"Fertility Preservation Using Tamoxifen and Letrozole in Estrogen Sensitive Tumors Trial","has_exemption":false,"start_date":"2016-07-21","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"University of California, San Francisco","sponsor_slug":"university-of-california-san-francisco","status":"ongoing","is_pact":true,"days_late":null},{"registry_id":"NCT02724579","publication_url":"https://clinicaltrials.gov/study/NCT02724579","title":"A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients","has_exemption":false,"start_date":"2017-11-17","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"Children's Oncology Group","sponsor_slug":"childrens-oncology-group","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT03682289","publication_url":"https://clinicaltrials.gov/study/NCT03682289","title":"Phase II Trial of Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Selected Solid Tumor Malignancies","has_exemption":false,"start_date":"2019-01-17","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"Rahul Aggarwal","sponsor_slug":"rahul-aggarwal","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT03865290","publication_url":"https://clinicaltrials.gov/study/NCT03865290","title":"Effects of Ondansetron on Gastrointestinal Sensorimotor Dysfunctions in Diabetes Mellitus and Dyspepsia","has_exemption":false,"start_date":"2019-04-02","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"Mayo Clinic","sponsor_slug":"mayo-clinic","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT03998254","publication_url":"https://clinicaltrials.gov/study/NCT03998254","title":"A Phase 3 Randomized, Double-Blinded, Controlled With GARDASIL® Efficacy, Immunogenicity and Safety Study of V503 [a 9-Valent HPV Vaccine] in Chinese Women 20 to 45 Years of Age","has_exemption":false,"start_date":"2019-06-26","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"Merck Sharp & Dohme LLC","sponsor_slug":"merck-sharp-dohme-llc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT04099056","publication_url":"https://clinicaltrials.gov/study/NCT04099056","title":"Brain Stimulation Studies of Decision-making Using Repetitive Transcranial Magnetic Stimulation (rTMS) and Temporal Interference (TI)","has_exemption":false,"start_date":"2019-11-11","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"Emory University","sponsor_slug":"emory-university","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT04261712","publication_url":"https://clinicaltrials.gov/study/NCT04261712","title":"An Open Label, Long-term Extension Study to Evaluate the Safety and Efficacy of CRN00808 in Subjects With Acromegaly (ACROBAT Advance)","has_exemption":false,"start_date":"2020-01-29","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"Crinetics Pharmaceuticals Inc.","sponsor_slug":"crinetics-pharmaceuticals-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT04248452","publication_url":"https://clinicaltrials.gov/study/NCT04248452","title":"A Phase III Study of Consolidative Radiotherapy in Patients With Oligometastatic HER2 Negative Esophageal and Gastric Adenocarcinoma (EGA)","has_exemption":false,"start_date":"2020-05-26","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"ECOG-ACRIN Cancer Research Group","sponsor_slug":"ecog-acrin-cancer-research-group","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT04560803","publication_url":"https://clinicaltrials.gov/study/NCT04560803","title":"Using Autologous Epidermal Skin Micrografts to Improve Healing In Radiation Wounds: A Pilot Study","has_exemption":false,"start_date":"2021-01-19","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"Massachusetts General Hospital","sponsor_slug":"massachusetts-general-hospital","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT04230356","publication_url":"https://clinicaltrials.gov/study/NCT04230356","title":"A Randomized Trial of Scheduled Versus Treatment Administration of Donor-Derived Viral Specific T-cells (VSTs) for Control of Viral Infections After Allogeneic Stem Cell Transplant","has_exemption":false,"start_date":"2021-01-27","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"Children's Hospital Medical Center, Cincinnati","sponsor_slug":"childrens-hospital-medical-center-cincinnati","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT04408638","publication_url":"https://clinicaltrials.gov/study/NCT04408638","title":"A Phase III, Open-Label, Multicenter, Randomized Study Evaluating the Efficacy and Safety of Glofitamab in Combination With Gemcitabine Plus Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma","has_exemption":false,"start_date":"2021-02-23","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"Hoffmann-La Roche","sponsor_slug":"hoffmann-la-roche","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT04696029","publication_url":"https://clinicaltrials.gov/study/NCT04696029","title":"Phase II Trial of Eflornithine/DFMO as Maintenance Therapy for Molecular High Risk/Very High Risk and Relapsed/Refractory Medulloblastoma","has_exemption":false,"start_date":"2021-03-29","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"Giselle Sholler","sponsor_slug":"giselle-sholler","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT04848506","publication_url":"https://clinicaltrials.gov/study/NCT04848506","title":"A Follow-Up, Open-Label, Research Evaluation of Sustained Treatment With Aficamten (CK-3773274) in Hypertrophic Cardiomyopathy (HCM)","has_exemption":false,"start_date":"2021-05-06","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"Cytokinetics","sponsor_slug":"cytokinetics","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT04486833","publication_url":"https://clinicaltrials.gov/study/NCT04486833","title":"A Phase 1/2 Open-Label, Dose-Escalation and Clinical Response Study of Quaratusugene Ozeplasmid in Combination With Osimertinib in Patients With Advanced, Metastatic EGFR-Mutant, Metastatic Non-Small Cell Lung Cancer","has_exemption":false,"start_date":"2021-09-03","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"Genprex, Inc.","sponsor_slug":"genprex-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05150704","publication_url":"https://clinicaltrials.gov/study/NCT05150704","title":"Single Blind Randomized Controlled Trial to Assess the Safety and Efficacy of High Dose Pulse Intravenous Corticosteroid Therapy to Treat Patients With Complicated/Fulminant Acute Myocarditis","has_exemption":false,"start_date":"2021-10-07","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"Niguarda Hospital","sponsor_slug":"niguarda-hospital","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT04982419","publication_url":"https://clinicaltrials.gov/study/NCT04982419","title":"Remote Ischemic Preconditioning for Renal and Cardiac Protection in Congestive Heart Failure (RICH) Trial","has_exemption":false,"start_date":"2021-11-01","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"VA Office of Research and Development","sponsor_slug":"va-office-of-research-and-development","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT04840602","publication_url":"https://clinicaltrials.gov/study/NCT04840602","title":"A Phase II Randomized Study Comparing BTK Inhibitors (Ibrutinib Plus Rituximab or Zanubrutinib Alone) vs. BCL-2 Inhibitor (Venetoclax) and Rituximab in Previously Untreated Waldenström's Macroglobulinemia (WM) / Lymphoplasmacytic Lymphoma (LPL)","has_exemption":false,"start_date":"2022-01-05","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"National Cancer Institute (NCI)","sponsor_slug":"national-cancer-institute-nci","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT04977180","publication_url":"https://clinicaltrials.gov/study/NCT04977180","title":"Phase II Trial of Cardioprotective Prophylaxis With Combination of Beta Blocker and Angiotensin-Converting Enzyme Inhibitors During Intensive Chemotherapy for Patients With Newly Diagnosed Acute Myeloid Leukemia","has_exemption":false,"start_date":"2022-03-04","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"University of Virginia","sponsor_slug":"university-of-virginia","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT04928846","publication_url":"https://clinicaltrials.gov/study/NCT04928846","title":"A Phase 3 Open-Label, Randomized, Controlled, Global Study of Telisotuzumab Vedotin (ABBV-399) Versus Docetaxel in Subjects With Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer","has_exemption":false,"start_date":"2022-03-25","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"AbbVie","sponsor_slug":"abbvie","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05269381","publication_url":"https://clinicaltrials.gov/study/NCT05269381","title":"A Phase I/II Study of Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab in Advanced Solid Tumors (PNeoVCA)","has_exemption":false,"start_date":"2022-03-31","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"Mayo Clinic","sponsor_slug":"mayo-clinic","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05376267","publication_url":"https://clinicaltrials.gov/study/NCT05376267","title":"Pediatric Influence of Cooling Duration on Efficacy in Cardiac Arrest Patients (P-ICECAP)","has_exemption":false,"start_date":"2022-08-05","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"University of Michigan","sponsor_slug":"university-of-michigan","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05523947","publication_url":"https://clinicaltrials.gov/study/NCT05523947","title":"A Phase 1/2, Open-label, Multicenter, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of YH32367 in Patients With HER2-Positive Locally Advanced or Metastatic Solid Tumors","has_exemption":false,"start_date":"2022-08-26","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"Yuhan Corporation","sponsor_slug":"yuhan-corporation","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05504291","publication_url":"https://clinicaltrials.gov/study/NCT05504291","title":"Intravitreal Melphalan for Intraocular Retinoblastoma","has_exemption":false,"start_date":"2022-11-04","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"Children's Oncology Group","sponsor_slug":"childrens-oncology-group","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05581303","publication_url":"https://clinicaltrials.gov/study/NCT05581303","title":"A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Olpasiran on Major Cardiovascular Events in Participants With Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein(a)","has_exemption":false,"start_date":"2022-12-14","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"Amgen","sponsor_slug":"amgen","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05549297","publication_url":"https://clinicaltrials.gov/study/NCT05549297","title":"Phase 2/3 Randomized Study of Tebentafusp as Monotherapy and in Combination With Pembrolizumab Versus Investigator's Choice in HLA-A*02:01-positive Participants With Previously Treated Advanced Melanoma (TEBE-AM)","has_exemption":false,"start_date":"2022-12-19","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"Immunocore Ltd","sponsor_slug":"immunocore-ltd","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05723198","publication_url":"https://clinicaltrials.gov/study/NCT05723198","title":"A Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of Baricitinib in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata","has_exemption":false,"start_date":"2023-02-27","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"Eli Lilly and Company","sponsor_slug":"eli-lilly-and-company","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05711394","publication_url":"https://clinicaltrials.gov/study/NCT05711394","title":"A Phase 3, Multicenter, 12-Week, Double Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Atogepant for the Preventive Treatment of Episodic Migraine in Pediatric Subjects 6-17 Years of Age.","has_exemption":false,"start_date":"2023-05-01","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"AbbVie","sponsor_slug":"abbvie","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05764720","publication_url":"https://clinicaltrials.gov/study/NCT05764720","title":"A Prospective Trial of Stereotactic Adaptive Radiation Therapy for Borderline Resectable/Locally Advanced Pancreatic Cancer: An Individualized Approach to Minimizing Gastrointestinal Toxicity (ARTIA-Pancreas)","has_exemption":false,"start_date":"2023-05-14","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"Varian, a Siemens Healthineers Company","sponsor_slug":"varian-a-siemens-healthineers-company","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05889182","publication_url":"https://clinicaltrials.gov/study/NCT05889182","title":"A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Efficacy and Safety of Upadacitinib in Adult and Adolescent Subjects With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy","has_exemption":false,"start_date":"2023-06-21","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"AbbVie","sponsor_slug":"abbvie","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05871372","publication_url":"https://clinicaltrials.gov/study/NCT05871372","title":"Intracranial Investigation of Neural Circuity Underlying Human Mood","has_exemption":false,"start_date":"2023-07-03","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"Baylor College of Medicine","sponsor_slug":"baylor-college-of-medicine","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05796440","publication_url":"https://clinicaltrials.gov/study/NCT05796440","title":"An Extension Study to Monitor Long-Term Safety of LUM-201 Treatment in Children With Idiopathic Growth Hormone Deficiency","has_exemption":false,"start_date":"2023-08-01","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"Lumos Pharma","sponsor_slug":"lumos-pharma","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06019949","publication_url":"https://clinicaltrials.gov/study/NCT06019949","title":"Neuromodulatory Rehabilitation for Respiratory Motor Function in Individuals With Chronic Spinal Cord Injury","has_exemption":false,"start_date":"2023-09-10","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"University of Louisville","sponsor_slug":"university-of-louisville","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05848713","publication_url":"https://clinicaltrials.gov/study/NCT05848713","title":"AntiThrombotic Therapy to Ameliorate Clinical Complications in Community Acquired Pneumonia","has_exemption":false,"start_date":"2023-10-10","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"University of Manitoba","sponsor_slug":"university-of-manitoba","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06149403","publication_url":"https://clinicaltrials.gov/study/NCT06149403","title":"A Multi-center, Randomized, Active Controlled Clinical Trial to Evaluate the Efficacy and Safety of OTL-203 in Subjects With Mucopolysaccharidosis Type I, Hurler Syndrome (MPS-IH) Compared to Standard of Care With Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HSCT)","has_exemption":false,"start_date":"2023-12-11","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"Orchard Therapeutics","sponsor_slug":"orchard-therapeutics","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06118411","publication_url":"https://clinicaltrials.gov/study/NCT06118411","title":"A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy, Safety, and Tolerability of Upadacitinib in Adult and Adolescent Subjects With Non-Segmental Vitiligo Who Are Eligible for Systemic Therapy","has_exemption":false,"start_date":"2023-12-19","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"AbbVie","sponsor_slug":"abbvie","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06109467","publication_url":"https://clinicaltrials.gov/study/NCT06109467","title":"A Phase II Study Of Neratinib In Combination With Chemotherapy/Trastuzumab/Pembrolizumab In HER2 Overexpressing Gastroesophageal Cancers","has_exemption":false,"start_date":"2024-01-12","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"H. Lee Moffitt Cancer Center and Research Institute","sponsor_slug":"h-lee-moffitt-cancer-center-and-research-institute","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06225596","publication_url":"https://clinicaltrials.gov/study/NCT06225596","title":"A Randomized Open-Label Phase 2/3 Study of BT8009 as Monotherapy or in Combination in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)","has_exemption":false,"start_date":"2024-01-24","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"BicycleTx Limited","sponsor_slug":"bicycletx-limited","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05100641","publication_url":"https://clinicaltrials.gov/study/NCT05100641","title":"Randomized Phase 3 Trial of Standard Care Plus AV-GBM-1 vs Autologous Monocytes as Adjunctive Therapy Following Primary Surgery Plus Concurrent Radiation-temozolomide in Patients With Newly Diagnosed Glioblastoma","has_exemption":false,"start_date":"2024-01-31","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"Aivita Biomedical, Inc.","sponsor_slug":"aivita-biomedical-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06108934","publication_url":"https://clinicaltrials.gov/study/NCT06108934","title":"A Prospective, Pre-market, Multi-center Evaluation of the Clinical Outcomes of the Insignia Hip Stem in Total Hip Arthroplasty (THA)","has_exemption":false,"start_date":"2024-02-22","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"Stryker Australia Pty Ltd.","sponsor_slug":"stryker-australia-pty-ltd","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06223867","publication_url":"https://clinicaltrials.gov/study/NCT06223867","title":"Evaluation of Efficacy, Effectiveness, and Implementation of Jaspr Health's Digital Platform in Emergency Department for Patients With Suicidal Risk- Part A: Randomized Controlled Trial","has_exemption":false,"start_date":"2024-02-23","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"University of Massachusetts, Worcester","sponsor_slug":"university-of-massachusetts-worcester","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05692024","publication_url":"https://clinicaltrials.gov/study/NCT05692024","title":"COMMENCER: COffee and Metabolites Modulating the Gut MicrobiomE in Colorectal caNCER","has_exemption":false,"start_date":"2024-03-21","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"Massachusetts General Hospital","sponsor_slug":"massachusetts-general-hospital","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06309264","publication_url":"https://clinicaltrials.gov/study/NCT06309264","title":"Benefits of Speech-based Audiometry and Low-gain Hearing Aids for Blast-exposed Veterans","has_exemption":false,"start_date":"2024-04-01","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"VA Office of Research and Development","sponsor_slug":"va-office-of-research-and-development","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05823532","publication_url":"https://clinicaltrials.gov/study/NCT05823532","title":"Targeting Inflammation-Induced Changes in Brain Reward Signaling and Motivational Deficits in Patients With Schizophrenia Using an Anti-Inflammatory Challenge.","has_exemption":false,"start_date":"2024-04-18","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"Emory University","sponsor_slug":"emory-university","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05861986","publication_url":"https://clinicaltrials.gov/study/NCT05861986","title":"A Phase IV Open-Label Study Evaluating the Effectiveness and Safety of Risdiplam Administered as an Early Intervention in Pediatric Patients With Spinal Muscular Atrophy After Gene Therapy","has_exemption":false,"start_date":"2024-05-30","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"Hoffmann-La Roche","sponsor_slug":"hoffmann-la-roche","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06483334","publication_url":"https://clinicaltrials.gov/study/NCT06483334","title":"A Phase 1/2 Randomized, Umbrella Study to Evaluate the Efficacy and Safety of MK-2870 Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab, as Treatment for Participants With Advanced Urothelial Carcinoma (KEYMAKER-U04): Substudy 04C","has_exemption":false,"start_date":"2024-07-17","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"Merck Sharp & Dohme LLC","sponsor_slug":"merck-sharp-dohme-llc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06107062","publication_url":"https://clinicaltrials.gov/study/NCT06107062","title":"Hemp-derived Cannabidiol for the Treatment of Cannabis Use Disorder: A Double-blind Placebo-controlled Randomized Trial","has_exemption":false,"start_date":"2024-07-26","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"University of Colorado, Boulder","sponsor_slug":"university-of-colorado-boulder","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06428019","publication_url":"https://clinicaltrials.gov/study/NCT06428019","title":"A Prospective, Open-Label, Phase IIb/III Study to Evaluate the Risk of TLS and Optimization of the Initiation of Venetoclax in Combination With Obinutuzumab or Acalabrutinib With Different Ramp- Up Periods in Previously Untreated Subjects With CLL","has_exemption":false,"start_date":"2024-08-05","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"AbbVie","sponsor_slug":"abbvie","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06442566","publication_url":"https://clinicaltrials.gov/study/NCT06442566","title":"Sequential Trial of Adding Buprenorphine, Cognitive Behavioral Treatment, and Transcranial Magnetic Stimulation to Improve Outcomes of Long-Term Opioid Therapy for Chronic Pain (ACTION)","has_exemption":false,"start_date":"2024-08-12","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"Medical University of South Carolina","sponsor_slug":"medical-university-of-south-carolina","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06508658","publication_url":"https://clinicaltrials.gov/study/NCT06508658","title":"A Phase 3, Multicenter, Randomized, Open-Label Study of Epcoritamab Plus Lenalidomide Compared to Rituximab Plus Gemcitabine and Oxaliplatin in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma","has_exemption":false,"start_date":"2024-08-13","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"Genmab","sponsor_slug":"genmab","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05861999","publication_url":"https://clinicaltrials.gov/study/NCT05861999","title":"A Phase IV Open-Label Study Evaluating the Effectiveness and Safety of Risdiplam Administered in Pediatric Patients With Spinal Muscular Atrophy Who Experienced a Plateau or Decline in Function After Gene Therapy","has_exemption":false,"start_date":"2024-08-14","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"Hoffmann-La Roche","sponsor_slug":"hoffmann-la-roche","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06033950","publication_url":"https://clinicaltrials.gov/study/NCT06033950","title":"A Randomized, Double-blind, Placebo-controlled Pragmatic Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients with Heart Failure and Reduced Ejection Fraction Who Are Intolerant of or Not Eligible for Treatment with Steroidal Mineralocorticoid Receptor Antagonists (FINALITY-HF)","has_exemption":false,"start_date":"2024-08-20","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"Colorado Prevention Center","sponsor_slug":"colorado-prevention-center","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06096116","publication_url":"https://clinicaltrials.gov/study/NCT06096116","title":"Phase 3, Double-blind, Placebo-controlled, Multicentre Study on the Efficacy and Safety of Human Plasma Derived Antithrombin (Atenativ) in Heparin-Resistant Patients Scheduled to Undergo Cardiac Surgery Necessitating Cardiopulmonary Bypass","has_exemption":false,"start_date":"2024-08-21","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"Octapharma","sponsor_slug":"octapharma","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05667701","publication_url":"https://clinicaltrials.gov/study/NCT05667701","title":"Soy Isoflavones For Inner City Infants At Risk For Asthma (SIRA) Study","has_exemption":false,"start_date":"2024-09-18","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"Rajesh Kumar","sponsor_slug":"rajesh-kumar","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06053814","publication_url":"https://clinicaltrials.gov/study/NCT06053814","title":"A Phase 1/2, First in Human, Multiple-dose, 2-part Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NS-050/NCNP-03 in Boys With Duchenne Muscular Dystrophy (DMD)","has_exemption":false,"start_date":"2024-09-18","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"NS Pharma, Inc.","sponsor_slug":"ns-pharma-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06184750","publication_url":"https://clinicaltrials.gov/study/NCT06184750","title":"Refining Tamoxifen Dose for Premenopausal Breast Cancer Risk Reduction (RENAISSANCE): A Phase II Single Arm Trial","has_exemption":false,"start_date":"2024-09-27","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"National Cancer Institute (NCI)","sponsor_slug":"national-cancer-institute-nci","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06679270","publication_url":"https://clinicaltrials.gov/study/NCT06679270","title":"An Open-label Extension of APG-20 Study to Evaluate the Long-term Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects With Partial Lipodystrophy","has_exemption":false,"start_date":"2024-10-14","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"Amryt Pharma","sponsor_slug":"amryt-pharma","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT04530058","publication_url":"https://clinicaltrials.gov/study/NCT04530058","title":"The Effects of Metformin on Morbidity and Mortality in Elderly Patients- a Prospective Randomized Control Trial (RCT)","has_exemption":false,"start_date":"2024-11-30","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"Hamilton Health Sciences Corporation","sponsor_slug":"hamilton-health-sciences-corporation","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06679946","publication_url":"https://clinicaltrials.gov/study/NCT06679946","title":"An Open-Label Extension Study to Assess the Safety and Efficacy of Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy (ATTR Amyloidosis With Cardiomyopathy)","has_exemption":false,"start_date":"2024-12-03","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"Alnylam Pharmaceuticals","sponsor_slug":"alnylam-pharmaceuticals","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06381154","publication_url":"https://clinicaltrials.gov/study/NCT06381154","title":"MC230404 Photodynamic Priming to Facilitate Immunologic Activity of Anti-PD1 in Patients With Pancreatic Cancer","has_exemption":false,"start_date":"2024-12-06","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"Mayo Clinic","sponsor_slug":"mayo-clinic","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05427695","publication_url":"https://clinicaltrials.gov/study/NCT05427695","title":"Topical Probiotic Sinus Irrigations for the Treatment of Chronic Rhinosinusitis: a Double Blinded Randomized Controlled Trial","has_exemption":false,"start_date":"2025-02-05","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"University of Illinois at Chicago","sponsor_slug":"university-of-illinois-at-chicago","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06855212","publication_url":"https://clinicaltrials.gov/study/NCT06855212","title":"A Phase II Study of Neoadjuvant Cetuximab and Cemiplimab in Patients Undergoing Surgery for Head and Neck Squamous Cell Carcinoma","has_exemption":false,"start_date":"2025-02-26","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"H. Lee Moffitt Cancer Center and Research Institute","sponsor_slug":"h-lee-moffitt-cancer-center-and-research-institute","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06830044","publication_url":"https://clinicaltrials.gov/study/NCT06830044","title":"A Randomized, Double-Blind, Placebo-controlled Multicenter Study to Assess the Efficacy and Safety of Milsaperidone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder","has_exemption":false,"start_date":"2025-03-03","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"Vanda Pharmaceuticals","sponsor_slug":"vanda-pharmaceuticals","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06689085","publication_url":"https://clinicaltrials.gov/study/NCT06689085","title":"Open-Label, Multiple-Dose, 52-Week Study + 24-Month Long-Term Safety Extension to Evaluate the Safety, PK, & Efficacy of XYOSTED® for Testosterone Replacement in Male Adolescents With Deficiency or Absence of Endogenous Testosterone Due to Primary or Secondary Hypogonadism","has_exemption":false,"start_date":"2025-03-07","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"Halozyme Therapeutics","sponsor_slug":"halozyme-therapeutics","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06311214","publication_url":"https://clinicaltrials.gov/study/NCT06311214","title":"Optimizing Antibody-Drug Conjugate Therapy Through Molecular Analysis for Therapy Choice (ADC MATCH)","has_exemption":false,"start_date":"2025-03-18","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"National Cancer Institute (NCI)","sponsor_slug":"national-cancer-institute-nci","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06812832","publication_url":"https://clinicaltrials.gov/study/NCT06812832","title":"Simethicone as Part of an Enhanced Recovery After Surgery (ERAS) Protocol","has_exemption":false,"start_date":"2025-04-08","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"Madigan Army Medical Center","sponsor_slug":"madigan-army-medical-center","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06820463","publication_url":"https://clinicaltrials.gov/study/NCT06820463","title":"A Phase 2, Open-Label, Randomized, Master Protocol Study to Evaluate Safety and Efficacy of Multiple Treatment Combinations With Telisotuzumab Adizutecan in Subjects With Metastatic Colorectal Cancer","has_exemption":false,"start_date":"2025-04-24","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"AbbVie","sponsor_slug":"abbvie","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06414460","publication_url":"https://clinicaltrials.gov/study/NCT06414460","title":"A Phase 1/2, Open-Label, Multicenter, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics/Pharmacodynamics, and Preliminary Efficacy of ISM3412 in Participants With Locally Advanced/Metastatic Solid Tumors","has_exemption":false,"start_date":"2025-04-25","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"InSilico Medicine Hong Kong Limited","sponsor_slug":"insilico-medicine-hong-kong-limited","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06579196","publication_url":"https://clinicaltrials.gov/study/NCT06579196","title":"Evaluation of Trabedersen (OT-101) With Pembrolizumab in Patients With Newly Diagnosed Advanced Non-Small Cell Lung Cancer and Positive PD-L1","has_exemption":false,"start_date":"2025-05-12","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"University of Nebraska","sponsor_slug":"university-of-nebraska","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06702553","publication_url":"https://clinicaltrials.gov/study/NCT06702553","title":"Effect of Inhaled Nitric Oxide on Major Adverse Events Requiring Intensive Life Support in Adults Undergoing Cardiac Surgery With Cardiopulmonary Bypass: A Phase III, Double-Blind, Multicenter, Randomized Controlled Trial (Nitric Oxide for Reduced Intensive Support in Cardiac Surgery With Cardiopulmonary Bypass, the NORISC Trial)","has_exemption":false,"start_date":"2025-05-19","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"Xijing Hospital","sponsor_slug":"xijing-hospital","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06485843","publication_url":"https://clinicaltrials.gov/study/NCT06485843","title":"An Open Label Phase IIb Study to Evaluate Safety and Tolerability of OA-SYS in Subjects With Moderate to Severe Osteoarthritis of the Knee Joint","has_exemption":false,"start_date":"2025-05-21","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"Ageless Biotech, Inc.","sponsor_slug":"ageless-biotech-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06340568","publication_url":"https://clinicaltrials.gov/study/NCT06340568","title":"A Phase III, Randomized, Multi-site, Open-label Trial of BNT323/DB-1303 Versus Investigator's Choice of Chemotherapy in Previously Treated Patients With HER2- Expressing Recurrent Endometrial Cancer","has_exemption":false,"start_date":"2025-06-10","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"Biontech SE","sponsor_slug":"biontech-se","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07075718","publication_url":"https://clinicaltrials.gov/study/NCT07075718","title":"Phase 2/Phase 3 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant","has_exemption":false,"start_date":"2025-06-12","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"Glaukos Corporation","sponsor_slug":"glaukos-corporation","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06951594","publication_url":"https://clinicaltrials.gov/study/NCT06951594","title":"Iowa Cochlear Implant Clinical Research Center Study on Robotic-Assisted Versus Manual Electrode Array Insertion","has_exemption":false,"start_date":"2025-06-30","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"University of Iowa","sponsor_slug":"university-of-iowa","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07045909","publication_url":"https://clinicaltrials.gov/study/NCT07045909","title":"A Phase 2, Open-label, Multicenter Multi-cohort Study to Evaluate the Efficacy and Safety of Anitocabtagene Autoleucel in Participants With Newly Diagnosed Multiple Myeloma","has_exemption":false,"start_date":"2025-06-30","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"PETHEMA Foundation","sponsor_slug":"pethema-foundation","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06356155","publication_url":"https://clinicaltrials.gov/study/NCT06356155","title":"A Phase II, Open-label, Single-arm, Multi-center Study of Neoadjuvant Enfortumab Vedotin and Pembrolizumab in Cisplatin-eligible Upper Tract Urothelial Cancer (NEPTUNE)","has_exemption":false,"start_date":"2025-07-22","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"University of Michigan Rogel Cancer Center","sponsor_slug":"university-of-michigan-rogel-cancer-center","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06850805","publication_url":"https://clinicaltrials.gov/study/NCT06850805","title":"A 12-Week Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Intranasal Administration of 186 mcg of OPN-375 Twice a Day (BID) in Adolescent Subjects With Chronic Rhinosinusitis Without Nasal Polyps","has_exemption":false,"start_date":"2025-07-28","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"Optinose US Inc.","sponsor_slug":"optinose-us-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06959524","publication_url":"https://clinicaltrials.gov/study/NCT06959524","title":"AGENT DCB STANCE: AGENT Drug-Coated Balloon for STent AvoidANCE in PCI for De Novo Coronary Artery Disease","has_exemption":false,"start_date":"2025-08-21","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"Boston Scientific Corporation","sponsor_slug":"boston-scientific-corporation","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07114380","publication_url":"https://clinicaltrials.gov/study/NCT07114380","title":"Investigation of Cold Snare Polypectomy for Removing 10-20 mm 0-Ip Colorectal Polyp: One Feasibility and Safety Study","has_exemption":false,"start_date":"2025-08-25","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"National Taiwan University Hospital","sponsor_slug":"national-taiwan-university-hospital","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07023835","publication_url":"https://clinicaltrials.gov/study/NCT07023835","title":"A Phase 2b, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Usnoflast Administered to Adult Subjects With ALS","has_exemption":false,"start_date":"2025-09-17","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"Zydus Therapeutics Inc.","sponsor_slug":"zydus-therapeutics-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07202884","publication_url":"https://clinicaltrials.gov/study/NCT07202884","title":"A Master Protocol to Investigate the Efficacy and Safety of Orforglipron Tablet Once Daily Compared With Placebo in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight","has_exemption":false,"start_date":"2025-09-30","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"Eli Lilly and Company","sponsor_slug":"eli-lilly-and-company","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07181837","publication_url":"https://clinicaltrials.gov/study/NCT07181837","title":"A Multi-Center, Open-label, Phase 1/2 Trial of the Safety and Efficacy of MVX-220 Gene Therapy Administered by Intra-Cisterna Magna Injection to Participants With Angelman Syndrome","has_exemption":false,"start_date":"2025-10-29","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"MavriX Bio, LLC","sponsor_slug":"mavrix-bio-llc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06699121","publication_url":"https://clinicaltrials.gov/study/NCT06699121","title":"A Phase 2 Randomized, Double Blind, Placebo Controlled, Parallel Study Evaluating the Safety and Efficacy of LB P8 in Patients With Primary Sclerosing Cholangitis (PSC)","has_exemption":false,"start_date":"2025-11-30","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"LISCure Biosciences","sponsor_slug":"liscure-biosciences","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07205601","publication_url":"https://clinicaltrials.gov/study/NCT07205601","title":"Phase 2a Assessment of Safety, Tolerability, and Efficacy of Repeated Dosing of Intracerebroventricular Injections of Ex Vivo Expanded, Autologous Adipose-Derived Stem Cells (RB-ADSCs) in Participants With Mild to Moderate Alzheimer's Disease","has_exemption":false,"start_date":"2025-11-30","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"Regeneration Biomedical, Inc.","sponsor_slug":"regeneration-biomedical-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06917313","publication_url":"https://clinicaltrials.gov/study/NCT06917313","title":"A Randomized Phase II Study to Evaluate the Efficacy of Fezolinetant in Reducing Vasomotor Symptoms in Women With Breast Cancer on Endocrine Therapy","has_exemption":false,"start_date":"2025-12-05","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"Yale University","sponsor_slug":"yale-university","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07219602","publication_url":"https://clinicaltrials.gov/study/NCT07219602","title":"A Placebo-Controlled, Double-Blind, Randomized, Phase 3 Study to Evaluate the Effect of Obicetrapib 10 mg and Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome (RUBENS Trial)","has_exemption":false,"start_date":"2025-12-11","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"NewAmsterdam Pharma","sponsor_slug":"newamsterdam-pharma","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06722183","publication_url":"https://clinicaltrials.gov/study/NCT06722183","title":"FUTURE Platform Trial - A Phase II Platform Trial of Futibatinib in Combination With (Chemo)Immunotherapy in Colorectal Cancer and Other Solid Tumor Entities","has_exemption":false,"start_date":"2025-12-16","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest","sponsor_slug":"institut-fur-klinische-krebsforschung-ikf-gmbh-at-krankenhaus-nordwest","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07225712","publication_url":"https://clinicaltrials.gov/study/NCT07225712","title":"A Multicenter, Uncontrolled, Open-label Trial to Evaluate the Tolerability, Safety, and Efficacy of Long-term Administration of SEP-363856 in Patients With Schizophrenia","has_exemption":false,"start_date":"2025-12-22","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"Otsuka Pharmaceutical Co., Ltd.","sponsor_slug":"otsuka-pharmaceutical-co-ltd","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07398417","publication_url":"https://clinicaltrials.gov/study/NCT07398417","title":"A Double-Blind, Placebo-Controlled, Randomized Withdrawal Study to Assess the Efficacy and Safety of AXS-14 in the Management of Fibromyalgia","has_exemption":false,"start_date":"2026-01-14","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"Axsome Therapeutics, Inc.","sponsor_slug":"axsome-therapeutics-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07183319","publication_url":"https://clinicaltrials.gov/study/NCT07183319","title":"Circulating Tumor DNA Response Adapted Treatment De-escalation Metastatic Urothelial Carcinoma (CT-READ)","has_exemption":false,"start_date":"2026-01-19","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"University of Oklahoma","sponsor_slug":"university-of-oklahoma","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07258407","publication_url":"https://clinicaltrials.gov/study/NCT07258407","title":"A Phase 1/2 Dose Escalation Trial With Administration Schedule Exploration Evaluating Single Agent TD001, a PSMA-Targeted Antibody-Drug Conjugate, in Patients With PSMA-Expressing Metastatic Castration-Resistant Prostate Cancer","has_exemption":false,"start_date":"2026-01-30","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"T.O.A.D. Oncology SA","sponsor_slug":"toad-oncology-sa","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT04901741","publication_url":"https://clinicaltrials.gov/study/NCT04901741","title":"An Open-label Phase 2 Study of Olaptesed Pegol (NOX-A12) Combined With Pembrolizumab and Nanoliposomal Irinotecan/5-FU/Leucovorin or Gemcitabine/Nab-paclitaxel in Microsatellite-stable Metastatic Pancreatic Cancer Patients","has_exemption":false,"start_date":"2026-01-31","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"TME Pharma AG","sponsor_slug":"tme-pharma-ag","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07322003","publication_url":"https://clinicaltrials.gov/study/NCT07322003","title":"A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Pridopidine in Participants With Amyotrophic Lateral Sclerosis","has_exemption":false,"start_date":"2026-02-01","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"Prilenia","sponsor_slug":"prilenia","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07321886","publication_url":"https://clinicaltrials.gov/study/NCT07321886","title":"A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Once Weekly Eloralintide in Adult Participants With Obesity or Overweight, Without Type 2 Diabetes","has_exemption":false,"start_date":"2026-02-06","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"Eli Lilly and Company","sponsor_slug":"eli-lilly-and-company","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07353931","publication_url":"https://clinicaltrials.gov/study/NCT07353931","title":"A Master Protocol for Phase 3 Randomized, Double-Blind, Placebo-Controlled Studies to Investigate the Efficacy and Safety of Once Weekly Eloralintide in Adult Participants With Osteoarthritis Knee Pain, and Obesity or Overweight (ENLIGHTEN-4)","has_exemption":false,"start_date":"2026-02-09","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"Eli Lilly and Company","sponsor_slug":"eli-lilly-and-company","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07369011","publication_url":"https://clinicaltrials.gov/study/NCT07369011","title":"A Master Protocol for Phase 3 Randomized, Double-Blind, Placebo-Controlled Studies to Investigate the Efficacy and Safety of Once Weekly Eloralintide in Adult Participants With Moderate to Severe Obstructive Sleep Apnea, and Obesity or Overweight","has_exemption":false,"start_date":"2026-02-10","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"Eli Lilly and Company","sponsor_slug":"eli-lilly-and-company","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07420283","publication_url":"https://clinicaltrials.gov/study/NCT07420283","title":"A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study With a Separate Open-label Cohort to Evaluate the Efficacy and Safety of Brenipatide as Adjunctive Treatment to Transmucosal Buprenorphine With or Without Naloxone in Early Recovery of Participants With Opioid Use Disorder (RENEW-Op-1)","has_exemption":false,"start_date":"2026-02-13","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"Eli Lilly and Company","sponsor_slug":"eli-lilly-and-company","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06842498","publication_url":"https://clinicaltrials.gov/study/NCT06842498","title":"A Phase 2 Dose Optimization Trial Evaluating a CD46-Targeted Antibody-Drug Conjugate (FG-3246) in Patients With Metastatic Castration-Resistant Prostate Cancer","has_exemption":false,"start_date":"2026-02-22","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"Kyntra Bio","sponsor_slug":"kyntra-bio","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07414745","publication_url":"https://clinicaltrials.gov/study/NCT07414745","title":"MDT-0123 Clinical Trial Targeting Patients Who Require Lumbar Vertebral Fusion in Japan","has_exemption":false,"start_date":"2026-02-28","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"Medtronic Spinal and Biologics","sponsor_slug":"medtronic-spinal-and-biologics","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07287150","publication_url":"https://clinicaltrials.gov/study/NCT07287150","title":"A Phase II, Randomized, Multicenter, Open-Label Study Evaluating the Efficacy and Safety of the Combination of Inavolisib Plus Enzalutamide Versus Physician's Choice of ARPI or Docetaxel in Patients With Metastatic Castration-Resistant Prostate Cancer","has_exemption":false,"start_date":"2026-03-11","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"Hoffmann-La Roche","sponsor_slug":"hoffmann-la-roche","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07477457","publication_url":"https://clinicaltrials.gov/study/NCT07477457","title":"OstEvo - Osteosarcoma Evolves","has_exemption":false,"start_date":"2026-03-11","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"Memorial Sloan Kettering Cancer Center","sponsor_slug":"memorial-sloan-kettering-cancer-center","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07542470","publication_url":"https://clinicaltrials.gov/study/NCT07542470","title":"Assessing Outcomes in Spinal Surgery Patients Who Receive Iceless Cryopneumatic Therapy Using the NICE1 Device as Compared to Standard of Care","has_exemption":false,"start_date":"2026-03-15","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"Sarasota Memorial Health Care System","sponsor_slug":"sarasota-memorial-health-care-system","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07339358","publication_url":"https://clinicaltrials.gov/study/NCT07339358","title":"Safety & Performance of the World Medica World Diverter Embolization Device","has_exemption":false,"start_date":"2026-03-31","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"World Medica USA, LLC","sponsor_slug":"world-medica-usa-llc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07401290","publication_url":"https://clinicaltrials.gov/study/NCT07401290","title":"The Safety and Efficacy of Direct SLT in Pseudoexfoliation Glaucoma","has_exemption":false,"start_date":"2026-03-31","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"Vance Thompson Vision","sponsor_slug":"vance-thompson-vision","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07263230","publication_url":"https://clinicaltrials.gov/study/NCT07263230","title":"An Open-label Single Center Study Evaluating the Safety and Efficacy of Roflumilast Foam 0.3% in Subjects With Hidradenitis Suppurativa","has_exemption":false,"start_date":"2026-04-01","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"Beth Israel Deaconess Medical Center","sponsor_slug":"beth-israel-deaconess-medical-center","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07389031","publication_url":"https://clinicaltrials.gov/study/NCT07389031","title":"Maralixibat for the trEatment of inTrAhePatic cHOlestasis of pRegnancy (METAPHOR)","has_exemption":false,"start_date":"2026-04-01","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"Imperial College London","sponsor_slug":"imperial-college-london","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07432659","publication_url":"https://clinicaltrials.gov/study/NCT07432659","title":"Add-On Efficacy of Home-Based Transcutaneous Tibial Nerve Stimulation Via the ZIDA Control Sock in Adults With Overactive Bladder on Preexisting Stable Pharmacotherapy","has_exemption":false,"start_date":"2026-04-17","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"Medical University of South Carolina","sponsor_slug":"medical-university-of-south-carolina","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07536269","publication_url":"https://clinicaltrials.gov/study/NCT07536269","title":"A Phase 2, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Crinecerfont in Pediatric Participants 3 Months to <4 Years of Age With Classic Congenital Adrenal Hyperplasia","has_exemption":false,"start_date":"2026-04-30","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"Neurocrine Biosciences","sponsor_slug":"neurocrine-biosciences","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07614321","publication_url":"https://clinicaltrials.gov/study/NCT07614321","title":"Is Silodosin Effective for Treating Lower Urinary Tract Symptoms in Female Patients With Multiple Sclerosis? A Randomized Controlled Trial","has_exemption":false,"start_date":"2026-04-30","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"Atlantic Health System","sponsor_slug":"atlantic-health-system","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07414992","publication_url":"https://clinicaltrials.gov/study/NCT07414992","title":"Neoadjuvant STereotActic Body Radiotherapy and Cemiplimab With or Without Fianlimab for Cisplatin-Ineligible or Cisplatin-Declining Patients With Muscle-Invasive Bladder Cancer (NeoSTAR Bladder)","has_exemption":false,"start_date":"2026-05-31","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"Memorial Sloan Kettering Cancer Center","sponsor_slug":"memorial-sloan-kettering-cancer-center","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07568145","publication_url":"https://clinicaltrials.gov/study/NCT07568145","title":"PREVENT Study: Promoting Resilience Via Early Neurostimulation After Trauma","has_exemption":false,"start_date":"2026-05-31","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"Emory University","sponsor_slug":"emory-university","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07602699","publication_url":"https://clinicaltrials.gov/study/NCT07602699","title":"A Multi-Site Trial of Tirzepatide for Smoking Cessation","has_exemption":false,"start_date":"2026-05-31","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"University of Southern California","sponsor_slug":"university-of-southern-california","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06137365","publication_url":"https://clinicaltrials.gov/study/NCT06137365","title":"A Randomized, Placebo-Controlled Clinical Trial of Once Daily Oral Cannabis for Weight Loss in Obese Individuals","has_exemption":false,"start_date":"2026-06-21","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"Joshua A. Lile, Ph.D.","sponsor_slug":"joshua-a-lile-phd","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07585968","publication_url":"https://clinicaltrials.gov/study/NCT07585968","title":"Safety and Effectiveness of the Sphere-9™ Catheter and Affera™ Ablation System for the Treatment of Ventricular Tachycardia","has_exemption":false,"start_date":"2026-06-30","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"Medtronic Cardiac Ablation Solutions","sponsor_slug":"medtronic-cardiac-ablation-solutions","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06605651","publication_url":"https://clinicaltrials.gov/study/NCT06605651","title":"A Phase II Proof of Concept Multicenter, Randomized, Double-Blind Study to Assess the Safety and Efficacy of Phage Therapy in Patients With Hip or Knee Prosthetic Joint Infection Due to Staphylococcus Aureus Treated by DAIR","has_exemption":false,"start_date":"2026-07-31","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"Phagenix","sponsor_slug":"phagenix","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07431307","publication_url":"https://clinicaltrials.gov/study/NCT07431307","title":"A Two-part Phase IIb Randomized, Multicenter, Open-label Comparative Study to Firstly Evaluate the Safety and Efficacy Trial of BV100 in Combination With Low Dose Polymyxin B Plus Ceftazidime/Avibactam, or Plus Cefiderocol Versus Best Available Therapy in Patients With Hospital-acquired Bacterial Pneumonia, Ventilator-associated Bacterial Pneumonia and Bloodstream Infection, Suspected or Confirmed to be Due to Carbapenem-resistant Acinetobacter Baumannii Calcoaceticus Complex (CRABC), and Secondly to Evaluate the Pharmacokinetics of BV100 in Combination With Low Dose Polymyxin B Plus Cefideroc","has_exemption":false,"start_date":"2026-07-31","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"BioVersys AG","sponsor_slug":"bioversys-ag","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07304102","publication_url":"https://clinicaltrials.gov/study/NCT07304102","title":"Assessment of GORE® EXCLUDER® IBE Plus Stent Graft Performance in Patients Undergoing Endovascular Iliac Revascularization","has_exemption":false,"start_date":"2026-09-30","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"W.L.Gore & Associates","sponsor_slug":"wlgore-associates","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07465757","publication_url":"https://clinicaltrials.gov/study/NCT07465757","title":"A Phase 2 Study of Alisertib in Combination With Paclitaxel in Patients With Small Cell Lung Cancer","has_exemption":false,"start_date":"2026-09-30","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"Puma Biotechnology, Inc.","sponsor_slug":"puma-biotechnology-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06792500","publication_url":"https://clinicaltrials.gov/study/NCT06792500","title":"Investigational Study of Glycerol Tributyrate in MELAS and LHON-Plus","has_exemption":false,"start_date":"2026-10-31","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"George Washington University","sponsor_slug":"george-washington-university","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05402384","publication_url":"https://clinicaltrials.gov/study/NCT05402384","title":"Evaluation of Efficacy and Safety of D-galactose Supplementation in SLC35A2-CDG, a Disorder of Hypogalactosylation","has_exemption":false,"start_date":"2027-01-31","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"Eva Morava-Kozicz","sponsor_slug":"eva-morava-kozicz","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT03678025","publication_url":"https://clinicaltrials.gov/study/NCT03678025","title":"Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer","has_exemption":false,"start_date":"2018-09-24","completion_date":"2028-04-01","has_results":false,"results_due":false,"sponsor_name":"SWOG Cancer Research Network","sponsor_slug":"swog-cancer-research-network","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT03947450","publication_url":"https://clinicaltrials.gov/study/NCT03947450","title":"Autologous Volar Fibroblast Injection Into the Stump Site of Amputees","has_exemption":false,"start_date":"2019-09-05","completion_date":"2028-04-01","has_results":false,"results_due":false,"sponsor_name":"Johns Hopkins University","sponsor_slug":"johns-hopkins-university","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT03984448","publication_url":"https://clinicaltrials.gov/study/NCT03984448","title":"Randomized Phase II/III Study of Venetoclax (ABT199) Plus Chemoimmunotherapy for MYC/BCL2 Double-Hit and Double Expressing Lymphomas","has_exemption":false,"start_date":"2019-10-22","completion_date":"2028-04-01","has_results":false,"results_due":false,"sponsor_name":"National Cancer Institute (NCI)","sponsor_slug":"national-cancer-institute-nci","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT03772028","publication_url":"https://clinicaltrials.gov/study/NCT03772028","title":"Phase III Randomized Clinical Trial for Stage III Epithelial Ovarian Cancer Randomizing Between Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy","has_exemption":false,"start_date":"2020-01-01","completion_date":"2028-04-01","has_results":false,"results_due":false,"sponsor_name":"The Netherlands Cancer Institute","sponsor_slug":"the-netherlands-cancer-institute","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT04752137","publication_url":"https://clinicaltrials.gov/study/NCT04752137","title":"Evaluation of Intraoperative Tumor Margin Identification With Fluorescent Dye Imaging","has_exemption":false,"start_date":"2022-05-25","completion_date":"2028-04-01","has_results":false,"results_due":false,"sponsor_name":"Massachusetts General Hospital","sponsor_slug":"massachusetts-general-hospital","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05764642","publication_url":"https://clinicaltrials.gov/study/NCT05764642","title":"Renal Microvessel Imaging for Characterization of Chronic Kidney Disease","has_exemption":false,"start_date":"2023-08-09","completion_date":"2028-04-01","has_results":false,"results_due":false,"sponsor_name":"Mayo Clinic","sponsor_slug":"mayo-clinic","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06062875","publication_url":"https://clinicaltrials.gov/study/NCT06062875","title":"Effects of TNF Blockade on Human BPH/LUTS","has_exemption":false,"start_date":"2024-01-24","completion_date":"2028-04-01","has_results":false,"results_due":false,"sponsor_name":"Endeavor Health","sponsor_slug":"endeavor-health","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06073665","publication_url":"https://clinicaltrials.gov/study/NCT06073665","title":"Levothyroxine Dosing in Older Individuals","has_exemption":false,"start_date":"2024-01-31","completion_date":"2028-04-01","has_results":false,"results_due":false,"sponsor_name":"University of Pennsylvania","sponsor_slug":"university-of-pennsylvania","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06350045","publication_url":"https://clinicaltrials.gov/study/NCT06350045","title":"Renal Puncture Above the Eleventh Rib (High Supracostal Approach) Versus Subcostal Puncture in Percutaneous Nephrolithotomy for Treatment of Renal Stones in Adults: A Prospective Randomized Trial","has_exemption":false,"start_date":"2024-03-01","completion_date":"2028-04-01","has_results":false,"results_due":false,"sponsor_name":"Assiut University","sponsor_slug":"assiut-university","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06150417","publication_url":"https://clinicaltrials.gov/study/NCT06150417","title":"Metastasis-directed Radiotherapy (MDRT) for Men With De-novo Oligometastatic Prostate Cancer Treated With Long-term Androgen Deprivation Therapy in the STAMPEDE Trial (METANOVA)","has_exemption":false,"start_date":"2024-07-01","completion_date":"2028-04-01","has_results":false,"results_due":false,"sponsor_name":"Case Comprehensive Cancer Center","sponsor_slug":"case-comprehensive-cancer-center","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06150599","publication_url":"https://clinicaltrials.gov/study/NCT06150599","title":"Sacral Neuromodulation for the Treatment of Chronic Pelvic Pain","has_exemption":false,"start_date":"2025-06-30","completion_date":"2028-04-01","has_results":false,"results_due":false,"sponsor_name":"Corewell Health East","sponsor_slug":"corewell-health-east","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07212062","publication_url":"https://clinicaltrials.gov/study/NCT07212062","title":"A Phase II, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Sfatey and Tolerability of X/T+X-EC vs. Placebo in Participants With Alzheimer's Disease Currently Treated With Lecanemab.","has_exemption":false,"start_date":"2025-12-01","completion_date":"2028-04-01","has_results":false,"results_due":false,"sponsor_name":"Neurology Office of South Florida","sponsor_slug":"neurology-office-of-south-florida","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06961084","publication_url":"https://clinicaltrials.gov/study/NCT06961084","title":"Comparison of I-124 PET/CT to I-123 Whole Body Imaging for the Diagnosis of Thyroid","has_exemption":false,"start_date":"2025-12-04","completion_date":"2028-04-01","has_results":false,"results_due":false,"sponsor_name":"Thomas Hope","sponsor_slug":"thomas-hope","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06853223","publication_url":"https://clinicaltrials.gov/study/NCT06853223","title":"A Randomized Trial of CCR5 Inhibition as a Complement to Lung Transplant Induction Immunosuppression","has_exemption":false,"start_date":"2025-12-07","completion_date":"2028-04-01","has_results":false,"results_due":false,"sponsor_name":"University of California, San Francisco","sponsor_slug":"university-of-california-san-francisco","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06822010","publication_url":"https://clinicaltrials.gov/study/NCT06822010","title":"A Phase II Trial of SeqUential GeMcitabine and MITomycin Treatment for Favorable High-Risk Upper Urinary Tract Urothelial Carcinoma (SUMMIT)","has_exemption":false,"start_date":"2026-03-06","completion_date":"2028-04-01","has_results":false,"results_due":false,"sponsor_name":"Rutgers, The State University of New Jersey","sponsor_slug":"rutgers-the-state-university-of-new-jersey","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07339163","publication_url":"https://clinicaltrials.gov/study/NCT07339163","title":"Efficacy of Booster Injection With Gardasil-9 Vaccine on Intersurgical Interval (ISI) for Adults With Recurrent Respiratory Papillomatosis (RRP)","has_exemption":false,"start_date":"2026-04-01","completion_date":"2028-04-01","has_results":false,"results_due":false,"sponsor_name":"Ohio State University","sponsor_slug":"ohio-state-university","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07492134","publication_url":"https://clinicaltrials.gov/study/NCT07492134","title":"Comparing Placebo Versus Antibiotics for Acute Uncomplicated Diverticulitis","has_exemption":false,"start_date":"2026-04-01","completion_date":"2028-04-01","has_results":false,"results_due":false,"sponsor_name":"Vanderbilt University Medical Center","sponsor_slug":"vanderbilt-university-medical-center","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07553442","publication_url":"https://clinicaltrials.gov/study/NCT07553442","title":"A Phase 2, Randomized, Double-blind, Placebo-controlled, Single Dose Study of the Efficacy, Pharmacodynamics, and Safety of ALN-AGT01 RVR in Adult Patients With Mild to Moderate Hypertension Pretreated With Zilebesiran","has_exemption":false,"start_date":"2026-04-27","completion_date":"2028-04-01","has_results":false,"results_due":false,"sponsor_name":"Alnylam Pharmaceuticals","sponsor_slug":"alnylam-pharmaceuticals","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07285473","publication_url":"https://clinicaltrials.gov/study/NCT07285473","title":"Low-dose Naltrexone (LDN) for the Treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): Dose-Finding","has_exemption":false,"start_date":"2026-09-01","completion_date":"2028-04-01","has_results":false,"results_due":false,"sponsor_name":"University of Alabama at Birmingham","sponsor_slug":"university-of-alabama-at-birmingham","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT04568616","publication_url":"https://clinicaltrials.gov/study/NCT04568616","title":"Phase II Study of Neoadjuvant ArOMatase Inhibitor Therapy for ER+ Breast Cancer (NAOMI)","has_exemption":false,"start_date":"2021-08-13","completion_date":"2028-04-02","has_results":false,"results_due":false,"sponsor_name":"Dartmouth-Hitchcock Medical Center","sponsor_slug":"dartmouth-hitchcock-medical-center","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07224477","publication_url":"https://clinicaltrials.gov/study/NCT07224477","title":"A Phase 2, Randomized, Double-Blind, Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V540A in Healthy Females 16 to 26 Years of Age","has_exemption":false,"start_date":"2026-07-20","completion_date":"2028-04-04","has_results":false,"results_due":false,"sponsor_name":"Merck Sharp & Dohme LLC","sponsor_slug":"merck-sharp-dohme-llc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05719441","publication_url":"https://clinicaltrials.gov/study/NCT05719441","title":"A Double-Blind, Randomized, Placebo-Controlled Clinical Trial of Combination HIV-Specific Broadly Neutralizing Monoclonal Antibodies Combined With ART Initiation During Acute HIV Infection to Induce HIV Remission","has_exemption":false,"start_date":"2024-08-19","completion_date":"2028-04-06","has_results":false,"results_due":false,"sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","sponsor_slug":"national-institute-of-allergy-and-infectious-diseases-niaid","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06646276","publication_url":"https://clinicaltrials.gov/study/NCT06646276","title":"A Randomized, Double Blind, Multicenter Phase 3 Trial of BMS-986489 (BMS-986012+Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide vs Atezolizumab in Combination With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).","has_exemption":false,"start_date":"2025-02-25","completion_date":"2028-04-06","has_results":false,"results_due":false,"sponsor_name":"Bristol-Myers Squibb","sponsor_slug":"bristol-myers-squibb","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06919965","publication_url":"https://clinicaltrials.gov/study/NCT06919965","title":"A Phase 3, Randomized, Open-label, Multicenter Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Investigator's Choice of Intravesical Chemotherapy in Participants With High-risk Non-muscle-invasive Bladder Cancer With Susceptible FGFR Alterations Who Had Received Intravesical Bacillus Calmette-Guérin (BCG)","has_exemption":false,"start_date":"2025-09-10","completion_date":"2028-04-06","has_results":false,"results_due":false,"sponsor_name":"Janssen Research & Development, LLC","sponsor_slug":"janssen-research-development-llc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07149207","publication_url":"https://clinicaltrials.gov/study/NCT07149207","title":"Intraoperative Molecular Imaging Using ICG for Head and Neck Tumors","has_exemption":false,"start_date":"2026-05-04","completion_date":"2028-04-07","has_results":false,"results_due":false,"sponsor_name":"Medical University of South Carolina","sponsor_slug":"medical-university-of-south-carolina","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07202247","publication_url":"https://clinicaltrials.gov/study/NCT07202247","title":"A Phase II Randomized Study of Interventions for Metabolic Protection Against Cardiometabolic Toxicity During Androgen Deprivation Therapy (IMPACT-ADT)","has_exemption":false,"start_date":"2026-01-23","completion_date":"2028-04-09","has_results":false,"results_due":false,"sponsor_name":"City of Hope Medical Center","sponsor_slug":"city-of-hope-medical-center","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT04789486","publication_url":"https://clinicaltrials.gov/study/NCT04789486","title":"Nano-SMART: An Adaptive Phase I-II Trial of AGuIX Gadolinium-based Nanoparticles With Stereotactic Magnetic Resonance-guided Adaptive Radiation Therapy for Centrally Located Lung Tumors and Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma","has_exemption":false,"start_date":"2021-05-27","completion_date":"2028-04-10","has_results":false,"results_due":false,"sponsor_name":"Dana-Farber Cancer Institute","sponsor_slug":"dana-farber-cancer-institute","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06784726","publication_url":"https://clinicaltrials.gov/study/NCT06784726","title":"Odronextamab for Relapsed/Refractory Large B-Cell Lymphomas Before Definitive Lymphoma-Directed Therapies","has_exemption":false,"start_date":"2025-09-04","completion_date":"2028-04-10","has_results":false,"results_due":false,"sponsor_name":"University of Washington","sponsor_slug":"university-of-washington","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07537153","publication_url":"https://clinicaltrials.gov/study/NCT07537153","title":"Genicular Artery Embolization for Patients With Mild-To-Moderate Knee Osteoarthritis","has_exemption":false,"start_date":"2026-05-31","completion_date":"2028-04-10","has_results":false,"results_due":false,"sponsor_name":"Northwestern University","sponsor_slug":"northwestern-university","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07231952","publication_url":"https://clinicaltrials.gov/study/NCT07231952","title":"A Phase II Study of Time-limited Combination of Pirtobrutinib, Venetoclax, and Rituximab in Treatment Naïve Patients With Waldenström's Macroglobulinemia (WM) / Lymphoplasmacytic Lymphoma (LPL) (PRoVen)","has_exemption":false,"start_date":"2025-11-11","completion_date":"2028-04-11","has_results":false,"results_due":false,"sponsor_name":"Memorial Sloan Kettering Cancer Center","sponsor_slug":"memorial-sloan-kettering-cancer-center","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06260683","publication_url":"https://clinicaltrials.gov/study/NCT06260683","title":"A Comprehensive Evaluation of Tobacco-Flavored vs. Non-Tobacco Flavored E-Cigarettes on Smoking Behavior","has_exemption":false,"start_date":"2024-04-10","completion_date":"2028-04-12","has_results":false,"results_due":false,"sponsor_name":"Ohio State University Comprehensive Cancer Center","sponsor_slug":"ohio-state-university-comprehensive-cancer-center","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06668181","publication_url":"https://clinicaltrials.gov/study/NCT06668181","title":"Open-Label, Single-Arm Trial to Evaluate the Pharmacokinetics and Safety of Bimekizumab in Pediatric Study Participants From 2 to Less Than 18 Years of Age With Active Juvenile Idiopathic Arthritis Subtypes Enthesitis-Related Arthritis (Including Juvenile-Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis","has_exemption":false,"start_date":"2025-03-11","completion_date":"2028-04-12","has_results":false,"results_due":false,"sponsor_name":"UCB Biopharma SRL","sponsor_slug":"ucb-biopharma-srl","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07149857","publication_url":"https://clinicaltrials.gov/study/NCT07149857","title":"A Phase 2 Multicohort Trial to Further Characterize the Efficacy and Safety of Ciltacabtagene Autoleucel","has_exemption":false,"start_date":"2025-10-03","completion_date":"2028-04-12","has_results":false,"results_due":false,"sponsor_name":"Janssen Research & Development, LLC","sponsor_slug":"janssen-research-development-llc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT04573478","publication_url":"https://clinicaltrials.gov/study/NCT04573478","title":"A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Atrasentan in Patients With IgA Nephropathy at Risk of Progressive Loss of Renal Function","has_exemption":false,"start_date":"2020-12-11","completion_date":"2028-04-14","has_results":false,"results_due":false,"sponsor_name":"Novartis Pharmaceuticals","sponsor_slug":"novartis-pharmaceuticals","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06533644","publication_url":"https://clinicaltrials.gov/study/NCT06533644","title":"A Phase 2a Multicenter, Dose-Escalation and Dose Optimization Study of SYNC-T Therapy SV-102 for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)","has_exemption":false,"start_date":"2025-05-29","completion_date":"2028-04-14","has_results":false,"results_due":false,"sponsor_name":"Syncromune, Inc.","sponsor_slug":"syncromune-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07023432","publication_url":"https://clinicaltrials.gov/study/NCT07023432","title":"Belzutifan's Role in Active Surveillance Versus Treatment for Indolentmetastatic Clear Cell Renal Ccell Carcinoma (BRAVE-RCC)","has_exemption":false,"start_date":"2025-11-17","completion_date":"2028-04-14","has_results":false,"results_due":false,"sponsor_name":"M.D. Anderson Cancer Center","sponsor_slug":"md-anderson-cancer-center","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT04515836","publication_url":"https://clinicaltrials.gov/study/NCT04515836","title":"Phase II Trial of Olaparib in Homologous Recombination Deficient (HRD) Malignant Mesothelioma","has_exemption":false,"start_date":"2021-02-19","completion_date":"2028-04-15","has_results":false,"results_due":false,"sponsor_name":"University of Chicago","sponsor_slug":"university-of-chicago","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT04988386","publication_url":"https://clinicaltrials.gov/study/NCT04988386","title":"An Open-Label Extension and Safety Monitoring Study of Acoramidis (AG10) in Participants With Symptomatic Transthyretin Amyloid Cardiomyopathy Who Completed the Phase 3 ATTRibute-CM Trial (AG10-301)","has_exemption":false,"start_date":"2021-10-27","completion_date":"2028-04-15","has_results":false,"results_due":false,"sponsor_name":"Eidos Therapeutics, a BridgeBio company","sponsor_slug":"eidos-therapeutics-a-bridgebio-company","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07156578","publication_url":"https://clinicaltrials.gov/study/NCT07156578","title":"A Long-Term, Open-Label Extension Study of Bivamelagon in Participants With Hypothalamic Obesity (HO)","has_exemption":false,"start_date":"2025-11-10","completion_date":"2028-04-15","has_results":false,"results_due":false,"sponsor_name":"Rhythm Pharmaceuticals, Inc.","sponsor_slug":"rhythm-pharmaceuticals-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07227857","publication_url":"https://clinicaltrials.gov/study/NCT07227857","title":"A Phase Ib/II First-in-human, Multicentre, Open-label, Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effect of Intrathecal S230815 in Pediatric Participants With KCNT1-related Developmental and Epileptic Encephalopathy","has_exemption":false,"start_date":"2025-11-24","completion_date":"2028-04-15","has_results":false,"results_due":false,"sponsor_name":"Institut de Recherches Internationales Servier","sponsor_slug":"institut-de-recherches-internationales-servier","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT03153449","publication_url":"https://clinicaltrials.gov/study/NCT03153449","title":"Multi-Center Clinical Evaluation of the ATTUNE Revision System in Complex Primary Total Knee Arthroplasty","has_exemption":false,"start_date":"2017-09-19","completion_date":"2028-04-17","has_results":false,"results_due":false,"sponsor_name":"DePuy Orthopaedics","sponsor_slug":"depuy-orthopaedics","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05859568","publication_url":"https://clinicaltrials.gov/study/NCT05859568","title":"Baseline Performance and Fitting Parameters for Sonova Products","has_exemption":false,"start_date":"2023-04-17","completion_date":"2028-04-17","has_results":false,"results_due":false,"sponsor_name":"Advanced Bionics","sponsor_slug":"advanced-bionics","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06973187","publication_url":"https://clinicaltrials.gov/study/NCT06973187","title":"A Phase 3, Open-Label, Randomized Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","has_exemption":false,"start_date":"2025-09-04","completion_date":"2028-04-17","has_results":false,"results_due":false,"sponsor_name":"BeOne Medicines","sponsor_slug":"beone-medicines","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07130903","publication_url":"https://clinicaltrials.gov/study/NCT07130903","title":"A Phase 2 Study of Amplitude-Modulated Radiofrequency Electromagnetic Fields (AM RF EMF) in Combination With Fruquintinib in Refractory Metastatic Colorectal Cancer","has_exemption":false,"start_date":"2025-09-10","completion_date":"2028-04-17","has_results":false,"results_due":false,"sponsor_name":"Barbara Ann Karmanos Cancer Institute","sponsor_slug":"barbara-ann-karmanos-cancer-institute","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06129864","publication_url":"https://clinicaltrials.gov/study/NCT06129864","title":"A Phase III, Randomized, Open-Label, Multi-Center, Global Study of Volrustomig (MEDI5752) as Sequential Therapy Versus Observation in Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma, Who Have Not Progressed Following Definitive Concurrent Chemoradiotherapy (eVOLVE-HNSCC)","has_exemption":false,"start_date":"2023-12-14","completion_date":"2028-04-18","has_results":false,"results_due":false,"sponsor_name":"AstraZeneca","sponsor_slug":"astrazeneca","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06907615","publication_url":"https://clinicaltrials.gov/study/NCT06907615","title":"An Open-label, Multi-center, Global Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX43 (Anti-PD-L1 ADC) in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC)","has_exemption":false,"start_date":"2025-06-09","completion_date":"2028-04-20","has_results":false,"results_due":false,"sponsor_name":"Shanghai Henlius Biotech","sponsor_slug":"shanghai-henlius-biotech","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07647328","publication_url":"https://clinicaltrials.gov/study/NCT07647328","title":"SERAFA-1: A Single Arm, Open Label, Multicentre, Phase IIIb Study Of Camizestrant Plus Ribociclib in 1st Line Treatment of ER Positive, HER2-negative Advanced Breast Cancer Patients","has_exemption":false,"start_date":"2026-05-26","completion_date":"2028-04-20","has_results":false,"results_due":false,"sponsor_name":"AstraZeneca","sponsor_slug":"astrazeneca","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07584967","publication_url":"https://clinicaltrials.gov/study/NCT07584967","title":"Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Safety and Efficacy of 2 Dose Levels of the Oral Ghrelin Receptor Agonist AC01 Over 12 Weeks in Patients With Chronic Advanced Heart Failure With Reduced Ejection Fraction (HFrEF)","has_exemption":false,"start_date":"2026-08-15","completion_date":"2028-04-22","has_results":false,"results_due":false,"sponsor_name":"AnaCardio AB","sponsor_slug":"anacardio-ab","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05984277","publication_url":"https://clinicaltrials.gov/study/NCT05984277","title":"A Phase III, Two-Arm, Parallel, Randomized, Multi-Center, Open-Label, Global Study to Determine the Efficacy of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for First-Line Treatment of Patients With Metastatic Non-Small Cell Lung Cancer (mNSCLC).","has_exemption":false,"start_date":"2023-10-24","completion_date":"2028-04-24","has_results":false,"results_due":false,"sponsor_name":"AstraZeneca","sponsor_slug":"astrazeneca","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06788938","publication_url":"https://clinicaltrials.gov/study/NCT06788938","title":"Tarlatamab in Advanced DLL3-Expressing Tumors Including Neuroendocrine Neoplasms","has_exemption":false,"start_date":"2025-03-21","completion_date":"2028-04-24","has_results":false,"results_due":false,"sponsor_name":"Jonsson Comprehensive Cancer Center","sponsor_slug":"jonsson-comprehensive-cancer-center","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06911502","publication_url":"https://clinicaltrials.gov/study/NCT06911502","title":"A Phase 3, Multicenter, Randomized, Open Label Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) Vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy","has_exemption":false,"start_date":"2025-07-28","completion_date":"2028-04-24","has_results":false,"results_due":false,"sponsor_name":"Celgene","sponsor_slug":"celgene","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07571746","publication_url":"https://clinicaltrials.gov/study/NCT07571746","title":"A Phase 2, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Surovatamig in Adults With Antibody-mediated Kidney Disease","has_exemption":false,"start_date":"2026-03-28","completion_date":"2028-04-24","has_results":false,"results_due":false,"sponsor_name":"AstraZeneca","sponsor_slug":"astrazeneca","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05536349","publication_url":"https://clinicaltrials.gov/study/NCT05536349","title":"Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)","has_exemption":false,"start_date":"2022-12-20","completion_date":"2028-04-25","has_results":false,"results_due":false,"sponsor_name":"M.D. Anderson Cancer Center","sponsor_slug":"md-anderson-cancer-center","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05939414","publication_url":"https://clinicaltrials.gov/study/NCT05939414","title":"An International, Prospective, Open-label, Multi-center, Randomized Phase III Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) Versus Observation to Delay Castration or Disease Recurrence in Adult Male Patients With Prostate-specific Membrane Antigen (PSMA) Positive Oligometastatic Prostate Cancer (OMPC)","has_exemption":false,"start_date":"2024-03-12","completion_date":"2028-04-25","has_results":false,"results_due":false,"sponsor_name":"Novartis Pharmaceuticals","sponsor_slug":"novartis-pharmaceuticals","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT04108624","publication_url":"https://clinicaltrials.gov/study/NCT04108624","title":"A Multimodality Approach to Minimal Residual Disease Detection to Guide Post-Transplant Maintenance Therapy in Multiple Myeloma (MRD2STOP)","has_exemption":false,"start_date":"2019-10-30","completion_date":"2028-04-26","has_results":false,"results_due":false,"sponsor_name":"University of Chicago","sponsor_slug":"university-of-chicago","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05519475","publication_url":"https://clinicaltrials.gov/study/NCT05519475","title":"A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors","has_exemption":false,"start_date":"2023-02-09","completion_date":"2028-04-27","has_results":false,"results_due":false,"sponsor_name":"Regeneron Pharmaceuticals","sponsor_slug":"regeneron-pharmaceuticals","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06435429","publication_url":"https://clinicaltrials.gov/study/NCT06435429","title":"A Phase 3, Randomized, Open-label, Multicenter, Controlled Study to Evaluate the Efficacy and Safety of Zanidatamab in Combination With Physician's Choice Chemotherapy Compared to Trastuzumab in Combination With Physician's Choice Chemotherapy for the Treatment of Participants With Metastatic HER2-positive Breast Cancer Who Have Progressed on, or Are Intolerant to, Previous Trastuzumab Deruxtecan Treatment","has_exemption":false,"start_date":"2024-08-13","completion_date":"2028-04-28","has_results":false,"results_due":false,"sponsor_name":"Jazz Pharmaceuticals","sponsor_slug":"jazz-pharmaceuticals","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07109219","publication_url":"https://clinicaltrials.gov/study/NCT07109219","title":"A Modular Phase I/II, Open-label, Multi-center Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of AZD4512 Monotherapy or in Combination With Anticancer Agent(s) in Participants With Acute Lymphoblastic Leukemia","has_exemption":false,"start_date":"2025-11-12","completion_date":"2028-04-28","has_results":false,"results_due":false,"sponsor_name":"AstraZeneca","sponsor_slug":"astrazeneca","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05974202","publication_url":"https://clinicaltrials.gov/study/NCT05974202","title":"Augmenting Cognitive-behavioral Therapy With rTMS of the Medial Prefrontal and Anterior Cingulate Cortices for the Treatment of Cocaine Use Disorder","has_exemption":false,"start_date":"2026-05-01","completion_date":"2028-04-28","has_results":false,"results_due":false,"sponsor_name":"New York State Psychiatric Institute","sponsor_slug":"new-york-state-psychiatric-institute","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07430605","publication_url":"https://clinicaltrials.gov/study/NCT07430605","title":"WearME-Pro Phase II: Remote Use Usability and Longitudinal Validation Study (Patch Form Factor)","has_exemption":false,"start_date":"2026-05-01","completion_date":"2028-04-28","has_results":false,"results_due":false,"sponsor_name":"LASARRUS Clinic and Research Center","sponsor_slug":"lasarrus-clinic-and-research-center","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07218354","publication_url":"https://clinicaltrials.gov/study/NCT07218354","title":"CSP #2041 - Cessation or Reduction of Alcohol Consumption in VEterans: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of a GLP-1 Receptor Agonist Semaglutide in U.S. Veterans With Alcohol Use Disorder (CRAVE)","has_exemption":false,"start_date":"2026-07-01","completion_date":"2028-04-28","has_results":false,"results_due":false,"sponsor_name":"VA Office of Research and Development","sponsor_slug":"va-office-of-research-and-development","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06071767","publication_url":"https://clinicaltrials.gov/study/NCT06071767","title":"A Phase I/IIa Randomized, Placebo-Controlled Trial of Conserved-Mosaic T-cell Vaccine in a Regimen With Vesatolimod and Broadly Neutralizing Antibodies in Adults Initiated on Suppressive Antiretroviral Therapy During Acute HIV-1","has_exemption":false,"start_date":"2024-04-01","completion_date":"2028-04-29","has_results":false,"results_due":false,"sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","sponsor_slug":"national-institute-of-allergy-and-infectious-diseases-niaid","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06358872","publication_url":"https://clinicaltrials.gov/study/NCT06358872","title":"Azithromycine Pour la Vie Des Enfants au Niger II","has_exemption":false,"start_date":"2024-04-29","completion_date":"2028-04-29","has_results":false,"results_due":false,"sponsor_name":"University of California, San Francisco","sponsor_slug":"university-of-california-san-francisco","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT01760005","publication_url":"https://clinicaltrials.gov/study/NCT01760005","title":"A Phase II/III Multicenter Randomized, Double-Blind, Placebo-Controlled Platform Trial of Potential Disease Modifying Therapies Utilizing Biomarker, Cognitive, and Clinical Endpoints in Dominantly Inherited Alzheimer's Disease","has_exemption":false,"start_date":"2012-12-31","completion_date":"2028-04-30","has_results":false,"results_due":false,"sponsor_name":"Washington University School of Medicine","sponsor_slug":"washington-university-school-of-medicine","status":"ongoing","is_pact":true,"days_late":null},{"registry_id":"NCT02718001","publication_url":"https://clinicaltrials.gov/study/NCT02718001","title":"Edwards EVOQUE Eos Mitral Valve Replacement: Investigation of Safety and Performance After Mitral Valve Replacement With Transcatheter Device (MISCEND)","has_exemption":false,"start_date":"2015-02-06","completion_date":"2028-04-30","has_results":false,"results_due":false,"sponsor_name":"Edwards Lifesciences","sponsor_slug":"edwards-lifesciences","status":"ongoing","is_pact":true,"days_late":null},{"registry_id":"NCT03128996","publication_url":"https://clinicaltrials.gov/study/NCT03128996","title":"A Phase I/II Trial of Reduced Intensity Conditioning and Familial HLA-Mismatched Bone Marrow Transplantation in Children With Non-Malignant Disorders","has_exemption":false,"start_date":"2017-03-20","completion_date":"2028-04-30","has_results":false,"results_due":false,"sponsor_name":"Washington University School of Medicine","sponsor_slug":"washington-university-school-of-medicine","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT03777267","publication_url":"https://clinicaltrials.gov/study/NCT03777267","title":"Cereset Research Exploratory Study","has_exemption":false,"start_date":"2019-04-12","completion_date":"2028-04-30","has_results":false,"results_due":false,"sponsor_name":"Wake Forest University Health Sciences","sponsor_slug":"wake-forest-university-health-sciences","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT04089059","publication_url":"https://clinicaltrials.gov/study/NCT04089059","title":"A Prospective, Multi-Center, Open Label, Single Arm Clinical Trial Evaluating the Safety and Efficacy of the Cordella™ Pulmonary Artery Sensor System in NYHA Class III Heart Failure Patients (PROACTIVE- HF Trial)","has_exemption":false,"start_date":"2020-01-10","completion_date":"2028-04-30","has_results":true,"results_due":false,"sponsor_name":"Endotronix, Inc.","sponsor_slug":"endotronix-inc","status":"reported","is_pact":false,"days_late":null},{"registry_id":"NCT04561401","publication_url":"https://clinicaltrials.gov/study/NCT04561401","title":"Can Brain Stimulation Enhance Outcomes Associated With Intensive Rehabilitation for Youth With Chronic Pain?","has_exemption":false,"start_date":"2020-10-19","completion_date":"2028-04-30","has_results":false,"results_due":false,"sponsor_name":"University of Calgary","sponsor_slug":"university-of-calgary","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT04725474","publication_url":"https://clinicaltrials.gov/study/NCT04725474","title":"A Phase 1/2, FIH, Two-part, Open-label Clinical Trial of Intravenous (IV) Administration of CTL-002 Given as Monotherapy and/or in Combination With an Anti-PD-1 Checkpoint Inhibitor in Subjects With Advanced-stage, Relapsed/Refractory Solid Tumors (The \"GDFATHER\"-Trial: GDF-15 Antibody-mediaTed Human Effector Cell Relocation).","has_exemption":false,"start_date":"2020-12-09","completion_date":"2028-04-30","has_results":false,"results_due":false,"sponsor_name":"CatalYm GmbH","sponsor_slug":"catalym-gmbh","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT04862286","publication_url":"https://clinicaltrials.gov/study/NCT04862286","title":"OptIMMize-2: A Phase 3 Multicenter, Single-arm, Open-label Extension Study to Assess the Safety, Tolerability, and Efficacy of Risankizumab in Subjects With Moderate to Severe Plaque Psoriasis Who Have Completed Participation in Study M19-977 (OptIMMize-1)","has_exemption":false,"start_date":"2021-07-24","completion_date":"2028-04-30","has_results":false,"results_due":false,"sponsor_name":"AbbVie","sponsor_slug":"abbvie","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT04899908","publication_url":"https://clinicaltrials.gov/study/NCT04899908","title":"A Double-blind, Phase II Randomized Study of Brain-directed Stereotactic Radiation With or Without AGuIX Gadolinium-based Nanoparticles in the Management of Brain Metastases at Higher Risk of Local Recurrence With Radiation Alone","has_exemption":false,"start_date":"2021-09-15","completion_date":"2028-04-30","has_results":false,"results_due":false,"sponsor_name":"Brigham and Women's Hospital","sponsor_slug":"brigham-and-womens-hospital","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05164172","publication_url":"https://clinicaltrials.gov/study/NCT05164172","title":"Long-term, Open-label (Dose-blinded), Extension Study of Eptinezumab in Children and Adolescents With Chronic or Episodic Migraine","has_exemption":false,"start_date":"2021-12-01","completion_date":"2028-04-30","has_results":false,"results_due":false,"sponsor_name":"H. Lundbeck A/S","sponsor_slug":"h-lundbeck-as","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05269394","publication_url":"https://clinicaltrials.gov/study/NCT05269394","title":"A Phase II/III Multicenter Randomized, Double-Blind, Placebo-Controlled Platform Trial of Potential Disease Modifying Therapies Utilizing Biomarker, Cognitive, and Clinical Endpoints in Dominantly Inherited Alzheimer's Disease","has_exemption":false,"start_date":"2021-12-22","completion_date":"2028-04-30","has_results":false,"results_due":false,"sponsor_name":"Washington University School of Medicine","sponsor_slug":"washington-university-school-of-medicine","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05321134","publication_url":"https://clinicaltrials.gov/study/NCT05321134","title":"Evaluation of SINGLE PORT (SP) Robotic Technology in Colorectal Surgery","has_exemption":false,"start_date":"2022-04-28","completion_date":"2028-04-30","has_results":false,"results_due":false,"sponsor_name":"University of California, Davis","sponsor_slug":"university-of-california-davis","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05243797","publication_url":"https://clinicaltrials.gov/study/NCT05243797","title":"Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation - MajesTEC-4","has_exemption":false,"start_date":"2022-09-08","completion_date":"2028-04-30","has_results":false,"results_due":false,"sponsor_name":"European Myeloma Network B.V.","sponsor_slug":"european-myeloma-network-bv","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT04922333","publication_url":"https://clinicaltrials.gov/study/NCT04922333","title":"Bisphosphonate Use to Mitigate Bone Loss Secondary to Bariatric Surgery","has_exemption":false,"start_date":"2023-03-28","completion_date":"2028-04-30","has_results":false,"results_due":false,"sponsor_name":"Wake Forest University Health Sciences","sponsor_slug":"wake-forest-university-health-sciences","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT04919629","publication_url":"https://clinicaltrials.gov/study/NCT04919629","title":"Randomized Phase 2 Trial of APL-2 With Pembrolizumab vs. APL-2 With Pembrolizumab and Bevacizumab vs. Bevacizumab Alone in Patients With Recurrent Ovarian Cancer and Persistent Malignant Effusion","has_exemption":false,"start_date":"2023-04-27","completion_date":"2028-04-30","has_results":false,"results_due":false,"sponsor_name":"Roswell Park Cancer Institute","sponsor_slug":"roswell-park-cancer-institute","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05681299","publication_url":"https://clinicaltrials.gov/study/NCT05681299","title":"Effects of Administration of Growth Hormone, Without and With Liraglutide, on AgRP, Energy and Glucose Metabolism in Healthy and GH Deficient Humans","has_exemption":false,"start_date":"2023-05-01","completion_date":"2028-04-30","has_results":false,"results_due":false,"sponsor_name":"Columbia University","sponsor_slug":"columbia-university","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05840211","publication_url":"https://clinicaltrials.gov/study/NCT05840211","title":"A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) (HER2 IHC0 or HER2-low [IHC 1+, IHC 2+/ISH-]) Inoperable, Locally Advanced, or Metastatic Breast Cancer and Have Received Endocrine Therapy","has_exemption":false,"start_date":"2023-05-08","completion_date":"2028-04-30","has_results":false,"results_due":false,"sponsor_name":"Gilead Sciences","sponsor_slug":"gilead-sciences","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05313243","publication_url":"https://clinicaltrials.gov/study/NCT05313243","title":"Phase 2 Study of Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory CD30 Positive T-cell Lymphoma","has_exemption":false,"start_date":"2023-07-10","completion_date":"2028-04-30","has_results":false,"results_due":false,"sponsor_name":"Yale University","sponsor_slug":"yale-university","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05540574","publication_url":"https://clinicaltrials.gov/study/NCT05540574","title":"Randomized Placebo-Controlled Crossover Trial of Zolpidem for Sleep in Children With Autism","has_exemption":false,"start_date":"2023-08-09","completion_date":"2028-04-30","has_results":false,"results_due":false,"sponsor_name":"Stanford University","sponsor_slug":"stanford-university","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06020716","publication_url":"https://clinicaltrials.gov/study/NCT06020716","title":"A Phase 4 Double Blinded Study With Two Different Interventions, Each With Two Arms, to Evaluate the Clinical Efficacy of Antibiotics and the Role of Microbiology, Immunology and Genetics in Children Aged 9-36 Months With Chronic Wet Cough.","has_exemption":false,"start_date":"2023-08-16","completion_date":"2028-04-30","has_results":false,"results_due":false,"sponsor_name":"Helse Stavanger HF","sponsor_slug":"helse-stavanger-hf","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05878860","publication_url":"https://clinicaltrials.gov/study/NCT05878860","title":"A Phase 1/2/3, Open-Label, Dose Escalation, Dose Expansion and Randomized, Controlled Study to Evaluate the Safety and Efficacy of ATSN-201 Gene Therapy in Subjects With RS1-Associated X-linked Retinoschisis (LIGHTHOUSE)","has_exemption":false,"start_date":"2023-08-22","completion_date":"2028-04-30","has_results":false,"results_due":false,"sponsor_name":"Atsena Therapeutics Inc.","sponsor_slug":"atsena-therapeutics-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05692635","publication_url":"https://clinicaltrials.gov/study/NCT05692635","title":"Reducing the Incidence of Symptomatic Brain Metastases With MRI Surveillance in Non-Squamous Locally Advanced Non-Small Cell Lung Cancer","has_exemption":false,"start_date":"2023-08-30","completion_date":"2028-04-30","has_results":false,"results_due":false,"sponsor_name":"Wake Forest University Health Sciences","sponsor_slug":"wake-forest-university-health-sciences","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06007183","publication_url":"https://clinicaltrials.gov/study/NCT06007183","title":"A Long-term Follow-up Study to Evaluate Safety and Immunogenicity of a Chikungunya Virus Virus-like Particle Vaccine (PXVX0317) in Healthy Adults and Adolescents After Either a Single or Booster Vaccination Dosing Regimen","has_exemption":false,"start_date":"2023-08-30","completion_date":"2028-04-30","has_results":false,"results_due":false,"sponsor_name":"Bavarian Nordic","sponsor_slug":"bavarian-nordic","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06092034","publication_url":"https://clinicaltrials.gov/study/NCT06092034","title":"Gene Therapy for Danon Disease: A Phase 2 Study Evaluating the Efficacy and Safety of Intravenously Administered Adeno-Associated Virus Serotype 9 (rAAV9) Vector Containing the Human LAMP2 Isoform B Transgene (RP-A501; AAV9.LAMP2B) in Male Patients With Danon Disease","has_exemption":false,"start_date":"2023-09-05","completion_date":"2028-04-30","has_results":false,"results_due":false,"sponsor_name":"Rocket Pharmaceuticals Inc.","sponsor_slug":"rocket-pharmaceuticals-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05948540","publication_url":"https://clinicaltrials.gov/study/NCT05948540","title":"A Phase 2, Multi-center, Multi-arm, Randomized, Placebo-controlled, Double-blind, Adaptive Platform Study to Evaluate the Safety, Tolerability, and Efficacy of Potential Pharmacotherapeutic Interventions in Active-Duty Service Members, Veterans, and Non-Veteran Civilians With PTSD","has_exemption":false,"start_date":"2023-11-02","completion_date":"2028-04-30","has_results":false,"results_due":false,"sponsor_name":"Global Coalition for Adaptive Research","sponsor_slug":"global-coalition-for-adaptive-research","status":"ongoing","is_pact":false,"days_late":null}]}